Biotech Company

Pharma Company

Type/Product Area

Amount

Terms Details

3-Dimensional Pharmaceuticals Inc.*

Heska Corp. (NASDAQ:HSKA)

Collaboration on use of 3-D¿s combinatorial chemistry, high-throughput screening and structure-based design technology to identify and optimize new pharmaceuticals for use in companion animals

$12.8M

Heska gets exclusive worldwide rights to products in veterinary markets; 3-D gets R&D funding and milestones over 5 years, plus royalties; 3-D retains exclusive rights to human applications of any compounds that result; for 1st product developed and approved, 3-D gets payments of $12.8M; 3-D gets additional milestones on 2nd approved product (12/97)

3-Dimensional Pharmaceuticals Inc.*

Wyeth-Ayerst Laboratories (division of American Home Products Corp.; NYSE:AHP)

Collaboration to develop 3-D¿s orally active thrombin inhibitors via structure-based drug design and combinatorial chemistry

$64M (equity; % ND)

Wyeth-Ayerst gets worldwide rights to 3-D¿s products now in preclinical development as well as any follow-on compounds discovered in collaboration; Wyeth-Ayerst will pay total of $64M for 1st product developed and approved under agreement and similar payments for 2nd product; 3-D gets royalties; Wyeth-Ayerst responsible for all development and other costs associated with program (6/97)

Abgenix Inc. (subsidiary of Cell Genesys Inc.)

Pfizer Inc. (NYSE:PFE)

Research collaboration and license agreement on use of Abgenix¿s transgenic XenoMouse technology to make fully human antibodies to 3 of Pfizer¿s antigen targets (undisclosed)

$30M (equity; % ND)

Abgenix gets license fee, equity investment, research funds and milestones totaling $30M; Pfizer responsible for product development, manufacturing and marketing worldwide; Abgenix gets royalties (12/97)

Acacia Biosciences Inc.*

Eli Lilly & Co. (NYSE:LLY)

Joint research collaboration; use of Acacia¿s Genome Reporter Matrix (GRM; uses yeast model organism and computer modeling) to aid in selection and optimization of drugs leads from a class of Lilly compounds

ND

Details ND (8/97)

Acadia Pharmaceuticals (formerly Receptor Technologies Inc.)*

Allergan Inc. (NYSE:AGN)

Joint research collaboration on drug discovery via Acadia¿s Receptor Selection and Amplification Technology (R-SAT) for functional analysis of recombinant targets; 5 targets include prostanoid and alphaadrenergic receptors as well as tissue-specific receptors in areas of interest to Allergan

$68.5M (12.5 0.000000e+00quity)

Allergan gets exclusive rights to develop and commercialize products for all therapeutic uses, but Acadia retained rights to at least 1 therapeutic indication for each target; Allergan will make $6M equity investment (12.5take); Acadia will get research funding for 3 years and milestones of $12.5M for 1st product for each receptor target; Acadia gets royalties on sales (9/97)

Affymetrix Inc.

Hoffmann-La Roche Ltd. (Switzerland)

Subscription-based supply agreement on Affymetrix¿s EasyAccess program (custom and standard GeneChip expression arrays) and related instrumentation; Roche will use technology in its drug discovery program

$15M

3-year agreement; Roche and its subsidiaries worldwide get broad access to EasyAccess as well as commercial genotyping and resequencing; Affymetrix gets $5M annually, beginning 1/1/98; Affymetrix also gets payments for custom GeneChip designs (8/97)

Affymetrix Inc.

Glaxo Wellcome plc (NYSE:GLX; U.K.)

HIV database agreement; use of Affymetrix¿s GeneChip technology to build database of genetic information from selected sample of HIV-infected patients (to understand correlation between viral mutations and response to antiviral drugs)

ND

Affymetrix will sell its non-proprietary DNA probe array to Glaxo Wellcome; the companies will initially build database on 1,600 HIV samples; if it proves useful, the collaboration will be expanded to collect data from tens of thousands of HIV patients taking antiviral drugs (or combinations); financial terms ND (1/97)

Affymetrix Inc.

Novartis Pharma AG (Switzerland)

Affymetrix will supply Novartis with its GeneChip instrumentation, software and DNA probe arrays (certain human and mouse genes) to monitor gene expression

ND

Affymetrix gets undisclosed payments based on per-data-point pricing model; payments will reflect number and nature of genes analyzed; further details ND (12/97)

Affymetrix Inc.

Parke-Davis (division of Warner- Lambert Co.; NYSE:WLA)

Affymetrix will supply Parke-Davis with its GeneChip arrays for monitoring gene expression

ND

Parke-Davis gets GeneChip instrumentation, software and standard DNA probe arrays as well as custom arrays that have genes select by Parke-Davis for use in its internal R&D; Affymetrix gets undisclosed access and design fees and per-chip payments (9/97)

Affymetrix Inc.

Pfizer Inc. (NYSE:PFE)

Affymetrix will supply Pfizer with its GeneChip instrumentation, software and custom DNA probe arrays containing genes selected by Pfizer

ND

Affymetrix gets undisclosed payment and could earn milestones if Pfizer develops a product (8/97)

Affymetrix Inc.

Roche Bioscience (division of Roche Holding Ltd.; Switzerland)

Agreement on use of Affymetrix¿s GeneChip technology to quantitatively detect differences in expression of human genes in various disease states

ND

Affymetrix will supply Roche Bioscience with GeneChip instruments and custom DNA probe arrays containing genes selected by Roche Bioscience (1/97)

Agritope Inc.

Vilmorin & Cie (majority owned subsidiary of Groupe Limagrain Holdings; France)

Research collaboration; Agritope will use seed varieties provided by Vilmorin in undisclosed projects

$7M (equity; % ND)

Vilmorin will buy $1.5M in Agritope preferred stock (0.2M shares) in a private placement and has option until 1/15/98 to buy 0.8M additional shares for $5.5M; Vilmorin will provide seeds and fund research projects; Vilmorin also has right of 1st refusal to fund research involving genetic modification of specified vegetables and flowers; further details ND (12/97)

Alanex Corp. (wholly owned subsidiary of Agouron Pharmaceuticals Inc.)

Roche Bioscience (division of Roche Holding Ltd.; Switzerland)

Agreement on use of Alanex¿s exploratory combinatorial libraries (small molecules with drug-like structures) for screening in Roche¿s biological assays for new drug leads

ND

In this 3-year agreement, Alanex will provide compounds from its library on non-exclusive basis to all 5 Roche global research organizations; Roche has right to exclusively license drug leads that arise; Alanex gets up-front technology access fee, annual research support, milestone payments and royalties (5/97)

Alliance Pharmaceutical Corp.

Schering AG (Germany)

License agreement on Alliance¿s ultrasound contrast agent Imagent US (aqueous dispersion of microbubbles containperfluorochemical vapor and physiological gas; completed Phase II trials in assessing cardiac function and detecting myocardial infraction)

$65M (equity; % ND)

Partners will jointly develop product; Schering gets exclusive worldwide marketing license; if product approved for marketing, Alliance gets $65M ($4M license fee, $10M in convertible preferred stock, milestones and reimbursement for development expenses); Schering gets exclusive manufacturing and marketing rights; Alliance gets royalties (agreement in principle 7/97; definitive agreement 9/97)

Alza Corp. and its R&D unit Therapeutic Discovery Corp. (which Alza has since reacquired)

The Ferring Group

Agreement to develop a non-scrotal transdermal testosterone product

ND

Alza exercised its option to license the product from Therapeutic Discovery; Ferring will market the non-scrotal product as well as Alza¿s Testoderm transdermal testosterone system in most European countries; Alza gets up-front payment and will manufacture and sell products to Ferring; Alza will make payments to Therapeutic Discovery based on sales (1/97)

Alza Corp. and its R&D unit Therapeutic Discovery Corp. (which Alza has since reacquired)

Knoll Pharmaceutical Co. and parent Knoll AG (Germany)

Agreement to develop and market an OROS (oral osmotic) formulation of hydromorphine for once-daily management of chronic pain

ND

Alza exercised its option to license the product from Therapeutic Discovery; Knoll is responsible for ongoing development costs and has worldwide commercialization rights; Alza gets up-front payment and milestones (which it will share with Therapeutic Discovery); Alza has co-promotion rights in U.S. and outside U.S. after Knoll¿s exclusivity period ends; Alza will manufacture and sell product to Knoll; Alza gets royalties (to be shared with Therapeutic Discovery) (2/97)

Amarillo Biosciences Inc.

Hayashibara Biochemical Laboratories (Japan)

License agreement on Hayashibara¿s natural interferon gamma and tumor necrosis factor alpha products for treating skin diseases

ND

ND (9/97)

Amarillo Biosciences Inc.

Hoffmann-La Roche Inc. (unit of Roche Holding Ltd.; Switzerland)

License on Roche¿s patents for human alpha interferon

ND

Amarillo licensed rights to make, have made, use and sell in U.S. preparations of interferon in dosage forms for treating human and animal diseases (7/97)

Amylin Pharmaceuticals Inc.

Hoechst Marion Roussel Inc. (subsidiary of Hoechst AG; Germany)

Amylin acquired rights to Hoechst Marion¿s series of orally active lipid-lowering agents (phenolic anti-oxidants), which it will evaluate for their ability to improve cardiovascular risk factors associated with atherosclerosis

ND

Amylin acquired exclusive worldwide rights; Amylin will conduct preclinical evaluation and clinical development; at end of Phase II trials, Hoechst Marion has option to collaborate in further product development in a 50/50 costand profit-sharing arrangement; if it exercises option, Amylin will be responsible for development and registration, Hoechst Marion for manufacturing and marketing; if Hoechst Marion does not exercise option, Amylin retains all rights and Hoechst Marion gets royalties; Amylin would then be free to collaborate with 3rd parties on development, manufacturing and commercialization (4/97)

Angiotech Pharmaceuticals Inc. (TSE:ANP; Canada)

Boston Scientific Corp. (NYSE:BSX) and Cook Inc.

Co-exclusive license on use of paclitaxel and related compounds applied as coatings for stents and other endoluminal devices for treating vascular and gastrointestinal diseases

$23.2M (equity; % ND)

Boston Scientific and Cook get co-exclusive worldwide license and will make equal equity investments in Angiotech; Angiotech also gets funds for product development, milestones and royalties; deal worth total US$23.2M pre-commercialization (7/97)

Aphton Corp.

Schering-Plough Animal Health (unit of ScheringPlough Corp.; NYSE:SGP)

Alliance to develop and commercialize Aphton¿s anti-gastrin 17 immunogen (product reduces stomach acid) for animal health market; 1st indication is equine ulcers

ND

Schering-Plough is responsible for funding all product development and marketing for each animal health indication; partners will share in all profits (8/97)

Appligene Oncor SA (France; subsidiary of Oncor Inc.)

Roche Molecular Systems Inc. and Hoffmann-La Roche Ltd. (Switzerland)

License agreement on Taq DNA polymerase and other Roche-patented enzymes, other thermostable enzymes and kits

ND

Appligene will develop, manufacture, use and sell products for use in research and for use in or conjunction with the PCR process; Oncor can use PCR in its DNA probe manufacturing processes (7/97)

Ariad Pharmaceuticals Inc.

Hoechst Marion Roussel Inc. (subsidiary of Hoechst AG; Germany)

Formation of 50/50 joint venture in functional genomics to be called the Hoechst-Ariad Genomics Center LLC; joint venture will analyze and identify genes that code for therapeutic proteins or targets for small-molecule drug discovery (each parent company will contribute its genomics expertise); initial targets in areas of bone, neurodegenerative, immune system and inflammatory disorders

$134M (12 0.000000e+00quity)

Ariad and Hoechst Marion Roussel (¿parent¿ firms) will jointly commit $85M over 5 years to fund research at joint venture; parents will share expenses equally; parents will also share rights to drug candidates; if either parent wants to seek a development/marketing partner for a lead product, it must first offer to negotiate with the other parent; Hoechst Marion will pay $24M for 2.5M shares of Ariad Series B convertible preferred stock (for 12take) at closing and may buy up to $25M more in future (but not to exceed 1.8M shares); the preferred stock contains lockup provisions for 6 years; the Genomics Center will be an installation site for Incyte Pharmaceuticals¿ LifeSeq database, to which each parent will subscribe (3/97)

Aronex Pharmaceuticals Inc.

Boehringer Mannheim GmbH (Germany)

Licensing agreement on Aronex¿s antibodytoxin complex AR 209 for treating breast cancer and other solid tumors; AR 209 is composed of ligand that binds to oncoprotein erbB-2 and fragment of Pseudomonas exotoxin

ND

Boehringer Mannheim will take over product development and gets exclusive rights to commercialize product; Aronex retains option for U.S. marketing rights; Aronex gets license fees, milestones and royalties; Aronex retains specific rights to the binding ligand of AR 209 (to develop additional cellular targeting products) (1/97)

ArQule Inc.

Monsanto Co. (NYSE:MTC)

Collaboration to develop agrochemicals via ArQule¿s Mapping Array and Directed Array compound sets; focus on herbicides, fungicides and insecticides

$12M

5-year collaboration; ArQule gets $12M in delivery fees for its arrays; ArQule will synthesize the Directed Array compound sets for use by Monsanto; ArQule gets milestones and royalties (1/97)

ArQule Inc.

Sankyo Co. Ltd. (Japan)

Broad collaboration to discover and optimize drug candidates for various therapeutic areas via ArQule¿s Mapping Array and Directed Array programs

$35M

Sankyo gets 3-year subscription to ArQule¿s programs to discover new lead compounds and then optimize them; ArQule gets payments for delivery of programs, milestones and royalties (11/97)

ArQule Inc.

Wyeth-Ayerst Pharmaceuticals (division of American Home Products Corp.; NYSE:AHP)

Broad collaboration to discover and optimize drug candidates for at least 15 of WyethAyerst¿s selected targets via ArQule¿s Mapping Array and Directed Array programs

$100M (<1 0.000000e+00quity)

5-year agreement; Wyeth-Ayerst will buy $2M in equity in 1998 (0.08M shares for less than 1take); ArQule gets yearly subscription fees totaling $26M as well as milestones; if 5 products reach FDA approval, ArQule could get $100M total pre-commercialization payments; ArQule also gets royalties (7/97)

Arris Pharmaceutical Corp. (since merged with Sequana Therapeutics Inc. to form Axys Pharmaceuticals Inc.)

Abbott Laboratories (NYSE:ABT)

Licensing of certain of Arris¿ drug discovery technologies to apply to specific Abbott target

ND

Arris gets license fees and royalties; Arris retained certain rights to transfer the technologies to other pharmaceutical firms in the future (6/97)

Arris Pharmaceutical Corp. (since merged with Sequana Therapeutics Inc. to form Axys Pharmaceuticals Inc.)

Bristol-Myers Squibb Co. (NYSE:BMY)

Agreement to develop protease inhibitors for hepatitis C virus (HCV), via Arris¿ Delta technology

ND

Bristol-Myers gets exclusive rights to any HCV protease inhibitors produced in collaboration; Arris gets research funding, up-front and milestone payments and royalties (12/97)

Atrix Laboratories Inc.

Pfizer Inc. (NYSE:PFE)

Feasibility study on use of Atrix¿s Atrigel drug delivery system (biodegradable polymer) to deliver an unnamed Pfizer drug as treatment for companion animals

ND

ND (3/97)

Aurora Biosciences Corp.

Eli Lilly & Co. (NYSE:LLY)

Collaborative research and licensing agreement to develop Aurora¿s ultra-high-throughput screening system (UHTSS) and to develop fluorescent screening technology

$20M

Lilly is the 2nd member of Aurora¿s co-sponsorship group to share in development costs of UHTSS; Lilly will provide $20M over 3 years, contingent in part on successful delivery of UHTSS; Aurora gets milestones and royalties; Lilly gets rights to use the UHTSS and Aurora¿s fluorescent screening technology (1/97)

Aurora Biosciences Corp.

Merck & Co. Inc. (NYSE:MRK)

Collaborative research and license agreement on Aurora¿s fluorescent assay technologies and its ultra-high-throughput screening system (UHTSS) as well as its screen development and screening services, which Merck will use in drug discovery

$100M

Merck will share in development cost of UHTSS and gets co-exclusive access; Aurora gets $33M in committed research funding, license fees and delivery payments; Aurora could get more than $100M if Merck exercises certain options for additional systems; Aurora also gets royalties on eventual product sales (12/97)

Aurora Biosciences Corp.

Parke-Davis (division of Warner-Lambert Co.; NYSE: WLA)

Collaborative research and license agreement on Aurora¿s fluorescent assay technologies and its ultra-high-throughput screening system (UHTSS), which ParkeDavis will use in drug discovery

$65M

Warner-Lambert will share in development cost of UHTSS and gets co-exclusive access; Aurora gets $25M over 3 years for license fees, research funding, screening services and UHTSS; Aurora also gets $40M in milestones, as well as possible additional payments from exercise of options to access additional screens; and royalties (9/97)

Avid Corp.*

The DuPont Merck Pharmaceutical Co.

Licensing agreement on DuPont Merck¿s 2ndgeneration HIV protease inhibitor (DMP 450) (Phase I trials completed)

ND

Avid licensed worldwide rights to compound; DuPont Merck gets up-front payment and is eligible for milestones and royalties; Avid will take over clinical development (1/97)

Avitech Diagnostics Inc.*

Amersham Pharmacia Biotech Ltd. (Sweden)

License agreement on Avitech¿s mutation scanning technology EMD for use in products for research and diagnostics (scans genes for disease-causing mutations)

ND

Amersham Pharmacia licensed worldwide rights to technology and will partner the technology with diagnostic product firms; Avitech retains rights to provide genome research, pharmacogenomic and diagnostic services (9/97)

Axiom Biotechnologies Inc.*

Zaiya Inc. and Nippon Kayaku Co. Ltd. (both Japan)

Joint collaboration to identify small molecule anticancer agents; use of Axiom¿s drug discovery technologies to evaluate compound libraries for lead agents that induce apoptosis in certain cancers (proprietary molecular target licensed by Zaiya)

ND

Axiom gets research funding for 3 years as well as license fees, milestones and royalties; Axiom will develop cell-based and biochemical assays coupled to its high-throughput pharmacology system (HT-PS) to accelerate functional profiling of hits; Nippon gets exclusive license for Asia and option to territories outside North America; Zaiya retains product rights in North America and will join with Axiom to find U.S. development and marketing partner (11/97)

Biogemma SA* (France)

Rhone-Poulenc Agro (unit of Rhone-Poulenc Group; France)

Letter of intent to create joint venture in plant biotech; focus on diseaseresistance, enhancement of gene libraries of certain plants and development of genetic engineering technologies

ND

Companies intend to create 50/50 joint venture within 6 months; companies will pool respective plant biotech research resources; financial terms ND (10/97)

Biogen Inc.

Merck & Co. Inc. (NYSE:MRK)

Collaborative research, development and license agreement on drugs for treating asthma and other inflammatory diseases; based on inhibiting VLA4 receptor molecules (found on most types of white blood cells); in particular, an aerosolized anti-VLA4 small molecule drug and oral VLA4 inhibitors

$145M

Biogen gets up-front payment of $15M plus $130M in milestones; Merck gets worldwide rights for certain indications, including asthma and Biogen gets worldwide rights for other indications, including multiple sclerosis and inflammatory bowel disease; Biogen will pay $21M in milestones to Merck for any of Biogen¿s indications; Merck¿s Japanese affiliate Banyu Pharmaceutical Co. Ltd. will manage clinical development and approvals in Japan of a Biogen compound (not yet selected) on which Biogen will retain Japanese marketing rights; final agreement subject to antitrust considerations (12/97)

Biorex Research and Development Co. (Hungary; wholly owned subsidiary of BRX Ltd.;U.K.)

Abbott Laboratories (NYSE:ABT)

Agreement for joint development of Biorex¿s bimoclomol product (synthetic small molecule that activates expression of heat shock proteins) for treating complications of diabetes (completed Phase II trials in U.K. and Hungary for treating microalbuminuria and diabetic neuropathy)

$28M (equity; % ND)

Abbott gets license to bimoclomal and related compounds; Abbott also gets option on right of first refusal on other future Biorex compounds; Abbott bought 26,200 non-voting convertible shares at $1,068.75/each in BRX Ltd.; Abbott will commercialize product; Biorex gets 10% royalty (letter of intent 10/97; definitive agreement 12/97)

BioSignal Inc.* (Canada)

Packard Bioscience Inc.

Strategic alliance that combines technology platforms for highthroughput screening of drug candidates for functional gene analysis; combines BioSignal¿s cloned genes and gene expression systems with Packard¿s instruments and reagents

$2.5M (19.8 0.000000e+00quity)

R&D project valued at $2.5M; Packard acquired 19.8 0.000000e+00quity stake and may increase that to 35 0n future (8/97)

Biota Holdings Ltd. (ASX:BTA; Australia)

Hitachi Chemical Co. Ltd. (Japan) and Nippon Chemiphar Co. (Japan)

Option agreement for Biota to develop a group of anticancer compounds that reactivate apoptosis in cancer cells (discovered by Hitachi); for treating prostate and other cancers

ND

If it exercises its option, Biota will take compounds through Phase II trials in Australia; Biota will get worldwide marketing rights outside Japan and specified countries in East Asia; Biota will pay milestones and royalties (to be shared by Japanese companies) (5/97)

Biotime Inc.

Abbott Laboratories (NYSE:ABT)

Licensing agreement on plasma expanding product Hextend (Phase III trials initiated 10/96)

$40M

Biotime gets up to $40M in fees; the 1st $1M is payable 45 days after signing; $1.5M payable on milestones; $37.5M payable based on annual net sales; Abbott will assist Biotime with Phase III trials; no further details (4/97)

Cadus Pharmaceutical Corp.

SmithKline Beecham plc (NYSE:SBH; U.K.)

Collaboration in functional genomics and newly detected G-coupled receptors; use Cadus¿ combinatorial library to identify ligands to the receptors; also to develop recombinant yeast strains for high-throughput screening

$68M (equity; % ND)

5-year agreement; Cadus will get $43M over 5 years (includes $10M in equity purchase, plus research funds and milestones); if initial term extended, Cadus could get $25M more in R&D funds and milestones; Cadus has co-promomotion rights in North America and for certain products that SmithKline decides not to pursue; Cadus gets royalties on sales (2/97)

Cambridge Antibody Technology Ltd. (U.K.)

Eli Lilly & Co. (NYSE:LLY)

Collaborative agreement on antibody-based therapeutics to certain of Lilly¿s targets; will use Cambridge Antibody¿s human single-chain antibody libraries

ND (includes equity)

Lilly gets license to Cambridge Antibody¿s antibody libraries and associated technologies; Lilly gets options to develop selected antibody-based therapeutics and diagnostics; Cambridge Antibody gets up-front license fee and additional fees, milestones and royalties; Cambridge Antibody also gets rights to develop antibody-based therapeutics to targets provided by Lilly; Lilly also bought equity (1/97)

Cantab Pharmaceuticals plc (U.K.)

Glaxo Wellcome plc (NYSE:GLX; U.K.)

Licensing agreement on Cantab¿s DISC HSV vaccine (genetically disabled live herpes simplex virus) for treating and preventing genital herpes

$17.5M (4 0.000000e+00quity)

Glaxo Wellcome gets exclusive worldwide rights to develop and market product; Cantab will get $17.5M (license fee of $8M and equity purchase of $9.5M for 0.62M new shares, or 4take); Glaxo Wellcome will pay all further development costs; Cantab will get milestones and royalties; Cantab retains right to copromote product in Europe (3/97)

Cell Genesys Inc.

Hoechst Marion Roussel Inc. (subsidiary of Hoechst AG; Germany)

Definitive agreement to license Cell Genesys¿ gene activation technology for erythropoietin gene and for one other (undisclosed) protein

$30M

Hoechst Marion intends to strengthen its patent position in this area; Cell Genesys got $4M on signing letter of intent (12/96) and will get $26M in fees and milestones, as well as royalties (3/97)

Chiron Corp.

AMRAD Corp. Ltd. (Australia)

R&D collaboration on use of AMRAD¿s virology and natural products screening programs to discover compounds for treating hepatitis C infection

$36M

Chiron will use AMRAD¿s drug discovery technologies; AMRAD could get US$36M (including milestones and royalties, but no up-front fee) in this 2-year collaboration (9/97)

Chiron Corp.

Biotech group of Baxter Healthcare Corp. (NYSE:BAX)

Agreement to develop and co-commercialize an ex vivo cell therapy product for treating leukemia; product will combine Chiron¿s gene therapy technology with Baxter¿s blood cell processing technology

ND

Chiron will develop a kit containing its TK retroviral vector, which will be used with Baxter¿s cell processing technology to produce donor lymphocytes containing the HSV-tk gene; Chiron responsible for clinical development and manufacturing of kit; Baxter has exclusive worldwide distribution rights; companies will co-promote product (1/97)

Chiron Corp.

Bristol-Myers Squibb Co. (NYSE:BMY) and Arris Pharmaceutical Corp.

Licenses to Chiron¿s hepatitis C (HCV) patent portfolio for protease inhibitor research (especially use of HCV NS3 protease)

ND

Bristol-Myers and Arris entered a collaboration to develop HCV protease inhibitors (see separate entry above); Chiron granted the partners the 1st non-exclusive licenses to its patents (12/97)

Chiron Technologies (business unit of Chiron Corp.)

Novartis Crop Protection (unit of Novartis AG; Switzerland)

Agreement to supply Novartis Crop with combinatorial chemistry libraries for use in selecting compounds for crop protection and animal health

ND

3-year agreement; Novartis Crop will support the chemical synthesis group at Chiron Technologies Pty Ltd. (Australia), which will synthesize selected combinatorial libraries; Novartis Crop will screen these in its own assays; Novartis Crop has option on exclusive worldwide license to active compounds and derivatives; Chiron gets initial and annual payments, milestones and royalties; Chiron retains rights to compounds for uses outside agriculture and veterinary medicine (9/97)

Chiroscience Group plc (U.K.)

Alcon Laboratories Inc. (wholly owned subsidiary of Nestle SA; France)

Research alliance on use of Chiroscience¿s directed compound libraries and highthroughput screening to develop small molecule drugs for undisclosed targets

ND

Alcon gets exclusive rights to ophthalmic applications of certain gene-based discoveries as well as access to topical ophthalmic applications of Chiroscience¿s existing compounds; Alcon retains rights to otic uses, also; Chiroscience has rights for all other uses; Alcon will make up-front payment and fund research (4/97)

Chiroscience Group plc (U.K.)

Hewlett-Packard Co. (NYSE:HP)

Letter of intent to design new system for DNA analysis by combining Mass Spectrometry Tag technology (developed at Darwin Discovery unit) with Hewlett-Packard¿s analytical instrumentation

ND

This is first commercial application of technologies that Chiroscience acquired with Darwin Molecular Corp. in 12/96; details ND (5/97)

Chiroscience Group plc (U.K.)

Powderject Pharmaceuticals plc (U.K.)

Agreement to develop anesthetic products (especially Lignocaine and Levobupivacaine) to be delivered in Powderject¿s drug injector technology

ND

Powderject will supply its drug injector technology; Chiroscience will manage and fund clinical trials; companies will split revenues equally (5/97)

Chiroscience Group plc (U.K.)

Schering-Plough Corp. (NYSE:SGP)

Agreement to develop selective phosphodiesterase IV (PDE IV) inhibitors as oral treatments for asthma and other inflammatory diseases (D4418 is currently in Phase I trials for asthma)

$38M

Schering-Plough gets exclusive worldwide rights to all products and has access to all of Chiroscience¿s PDE IV inhibitors, including D4418; Chiroscience gets up-front fee, R&D funding and milestones for total of $38M; Chiroscience also gets royalties (6/97)

Cima Labs Inc.

Bristol-Myers Squibb Co. (NYSE:BMY)

License agreement on use of Cima¿s OraSolv fast-dissolve, sustained release oral formulation for multiple products of Bristol-Myers

ND

Bristol-Myers gets non-exclusive worldwide license; Cima gets royalties on product sales (7/97)

Cima Labs Inc.

Novartis Consumer Health Inc. (division of Novartis AG; Switzerland)

Development and license option agreement on use of Cima¿s OraSolv drug delivery technology (microencapsulated drug formulated into fast-dissolving oral tablet) with Novartis consumer products

ND

ND (12/97)

Cima Labs Inc.

Schering Corp. (subsidiary of Schering-Plough Corp.; NYSE:SGP)

Development and license option agreement on use of Cima¿s OraSolv fast-dissolve, sustained-release oral formulation for one of Schering¿s marketed prescription drugs

ND

Cima gets option fee and development funding; other details ND (8/97)

CoCensys Inc.

Wyeth-Ayerst Laboratories (division of American Home Products Corp.; NYSE:AHP)

Licensing agreement on CO 2-6749 (synthetic version of epalon, which binds to GABA receptors in brain) for treating anxiety

$59M (equity; % ND)

Wyeth-Ayerst will fund all development of CO 2-6749 plus that of backup compound; Wyeth-Ayerst will pay $5M up-front license fee, buy $5M of convertible preferred stock (which converts any time after 2 years at Wyeth-Ayerst¿s option); CoCensys also gets funds for research on backup compounds of $3M/year for 3 years; CoCensys gets up to $40M in milestones; companies will co-promote products in U.S.; Wyeth-Ayerst has rights in rest of world; CoCensys gets royalties (5/97)

CollaGenex Pharmaceuticals Inc.

Heska Corp. (NASDAQ:HSKA)

Collaboration to develop certain of CollaGenex¿s chemically modified tetracyclines (inhibit matrix metalloproteinases) for use in companion animal health applications (osteoarthritis, cancer)

ND

ND (11/97)

CombiChem Inc. (IPO pending)

Sumitomo Pharmaceuticals Co. Ltd. (Japan)

Drug discovery and development agreement via CombiChem¿s Discovery Engine (molecular design and rapid synthesis) to generate drug leads for a molecular target that plays fundamental role in rheumatoid arthritis and osteoarthritis

$17M

CombiChem gets up-front payment, research funding and milestones totaling $17M; Sumitomo has exclusive worldwide rights to develop and market or sublicense products; CombiChem gets royalties (8/97)

Corixa Corp.

Pasteur Merieux Connaught (unit of Rhone Poulenc Group; France)

Collaboration on use of Corixa¿s protein adjuvant LeIF (Leishmanial eukaryotic initiation factor) in several of Pasteur Merieux Connaught¿s vaccines for infectious diseases

ND

Pasteur Merieux Connaught has right to license LeIF as an adjuvant; specific targets and terms of collaboration ND (3/97)

Corixa Corp.

SmithKline Beecham Biologicals SA (Belgium; unit of SmithKline Beecham plc; NYSE:SBH; U.K.)

Research collaboration and license agreement on Corixa¿s cancer vaccine discovery programs in breast and prostate cancer

ND

SmithKline gets exclusive worldwide rights to antigens discovered by Corixa in exchange for research funds, milestones and royalties; SmithKline has option to license additional Corixa vaccine technology for use in related fields (3/97)

Corvas International Inc.

Schering-Plough Corp. (NYSE:SGP)

Collaboration on orally bioavailable inhibitors of serine protease necessary for hepatitis C replication; Corvas will use its combinatorial chemistry program to identify and optimize lead protease inhibitors

ND

This is 3rd collaboration on protease inhibitors between the 2 parties; Schering-Plough gets exclusive worldwide rights to any products; Schering-Plough is responsible for all development, manufacturing and marketing; Corvas gets licensing fees, R&D funding, milestones and royalties (6/97)

Cubist Pharmaceuticals Inc.

Eli Lilly & Co. (NYSE:LLY)

Cubist acquired rights to Lilly¿s Daptomycin antibiotic to treat infections caused by drugresistant strains of Staphylococcus aureus and Enterococci

ND

Cubist licensed rights to develop, manufacture and market product; Cubist will conduct clinical trials; terms include up-front license fee, milestones and royalties (11/97)

CuraGen Corp. (IPO pending)

Pioneer Hi-Bred International Inc. (NYSE:PHB)

Major gene discovery collaboration; use of CuraGen¿s gene expression technology to identify genes responsible for superior performance in seeds; will examine 16 major agronomic traits in Pioneer-bred plants

$25M (equity; % ND)

Pioneer will make $7.5M equity investment and fund $17.5M in research over 5 years; Pioneer gets worldwide rights to develop and market seed and agricultural products; CuraGen retains rights to any human and animal health applications; each partner gets royalties on the other¿s sales; companies will also collaborate on enhancing CuraGen¿s GeneScape bioinformatics system (6/97)

Cytel Corp.

Immunotherapy division of biotech group of Baxter Healthcare Corp. (NYSE:BAX)

Clinical research collaboration for ex vivo cancer therapy; use of tumor-specific cytotoxic T cells (CTL) produced by activating patient¿s T cells ex vivo with tumorspecific peptide antigens (epitopes); initial focus on Phase I/II trial in malignant melanoma

ND

Cytel will provide melanomaspecific CTL-stimulatory peptides; Baxter will provide cell separation system and culture technology; Cytel and Baxter will jointly fund clinical study to be conducted by Physician Reliance Network Inc. (6/97)

Cytel Corp.

G.D. Searle & Co. (wholly owned subsidiary of Monsanto Co.; NYSE:MTC)

Letter of intent to collaborate on cancer therapies through Cytel¿s spin-off Epimmune Inc.; its vaccine technology includes library of antigenic cancer epitopes and immunostimulant technology (to create cancerspecific immune responses)

ND

Searle made immediate $5M investment in Cytel; Searle will also make substantial investments in Epimmune for research and preclinical development (9/97)

Cytogen Corp.

Boehringer Mannheim GmbH (Germany)

Licensing agreement on Cytogen¿s prostatespecific membrane antigen (PSMA) technology as well as the monoclonal antibody developed from it

ND

Boehringer Mannheim gets nonexclusive license to the antigen for in vitro diagnostics; Cytogen gets up-front fee and royalties on product sales (1/97)

Desmos Inc.*

Baxter Healthcare Corp. (subsidiary of Baxter International Inc.; NYSE:BAX)

Research collaboration on use of Desmos¿ extracellular matrix Desmosin (protein that plays key role in epithelial cell attachment and proliferation) as biocoating for epidermal attachment to percutaneous implants used in renal therapy

ND

Baxter will evaluate Desmos¿ technology; Baxter will fund initial phase of research at Desmos and has option on license covering further development and commercialization (9/97)

Digital Gene Technologies Inc.*

The Recordati Group (Italy)

Research collaboration to use Digital¿s total gene expression technology to evaluate antiatherogenic potential of Recordati¿s calcium channel blocker Lercanidipine; also to explore underlying causes of atherosclerosis

>$3M (equity; % ND)

Recordati will pay $3M up-front (including an undisclosed equity investment); Digital also gets milestones and royalties; parties will shares rights 50/50 to any other atherosclerosis target molecules identified in assays (4/97)

Dyax Corp.*

DuPont Merck Pharmaceutical Co.

License agreement on Dyax¿s phage display technology (method for creating large arrays of proteins and peptides, then rapidly selecting those with desired properties)

ND

Non-exclusive license includes signing fees, milestone payments and royalties; Dyax gets access to related patented technology owned by licensee (5/97)

Dyax Corp.*

Merck & Co. Inc. (NYSE:MRK)

Collaborative study agreement to discover and evaluate affinity ligands for vaccine purification via Dyax¿s phage display technology

ND

Dyax will develop affinity ligands; Merck will fund research and pay milestones and royalties to Dyax (10/97)

Dyax Corp.*

Monsanto Co. (NYSE:MTC)

License agreement on Dyax¿s phage display technology (method for creating large arrays of proteins and peptides, then rapidly selecting those with desired properties)

ND

Non-exclusive license includes signing fees, milestone payments and royalties; Dyax gets access to related patented technology owned by licensee (5/97)

Dyax Corp.*

Novo Nordisk A/S (NYSE:NVO; Denmark)

Collaboration to develop new research tools to accelerate evaluation of drug candidates; will use Dyax¿s phage display technology for Novo Nordisk¿s drug candidates

ND

Research phase of agreement is for 2 years; Novo Nordisk gets exclusive rights to products; further details ND (3/97)

Elan Pharmaceutical Technologies (division of Elan Corp. plc; Ireland)

Wyeth-Ayerst Laboratories (division of American Home Products Corp.; NYSE:AHP)

Research agreement to develop once-daily formulation of arthritis drug Lodine using Elan¿s IPDAS controlledrelease delivery system

ND

ND (4/97)

Emisphere Technologies Inc.

Eli Lilly & Co. (NYSE:LLY)

Strategic alliance to use Emisphere¿s technology for oral delivery of therapeutic proteins; therapeutic focus in endocrinology, including growth disorders

$60M

Emisphere will get $60M (consisting of initial fees, research funds and milestones) for oral formulations of 2 proteins; Emisphere may get additional payments for other delivery applications or if additional proteins are licensed; Lilly gets exclusive worldwide rights to commercialize any products; Emisphere gets royalties (2/97)

Emisphere Technologies Inc.

Novartis Pharma AG (Switzerland)

Collaboration on oral drug delivery of two selected large-molecule compounds of Novartis¿ (already on market)

$35M (equity; % ND)

Novartis gets exclusive worldwide rights to oral versions of drugs; Emisphere gets initial fees, equity investment (made in 4 tranches, with maximum aggregate purchase price of $16M), research funding and milestones totaling $35M in all; Emisphere also gets royalties (12/97)

Evotec BioSystems GmbH* (Germany)

Novartis AG (Switzerland)

Drug discovery collaboration using Evotec¿s ultra-high-throughput fluorescence-based screening system

ND

Details ND, but together with its alliance with SmithKline Beecham (announced simultaneously, see entry below), Evotec could get $30M in research funds (2/97)

Evotec BioSystems GmbH* (Germany)

SmithKline Beecham plc (NYSE:SBH; U.K.)

Drug discovery collaboration; to develop Evotec¿s ultra-high-throughput screening system (EVOscreen) to screen combinatorial compound libraries for drug candidates that interfere with or activate G-coupled receptors

ND

Details ND, but together with its alliance with Novartis (announced simultaneously, see above entry), Evotec could get $30M in research funds (2/97)

FibroGen Inc.*

Zeneca Ltd. (NYSE:ZEN; U.K.)

Licensing agreement on Zeneca compounds (not identified) as potential therapeutics for treating fibrotic disorders and diseases

ND

FibroGen gets exclusive license to develop and market these compounds outside of Europe and Japan, where Zeneca retains rights; other terms ND (10/97)

Gene Logic Inc.

Japan Tobacco Inc. (Japan)

Genomics collaboration; use of Gene Logic¿s Accelerated Drug Discovery platform to identify genes related to onset and progression of glomerulonephritis (renal disease) and to develop drug leads from them

$100.5M (equity; % ND)

Japan Tobacco will subscribe to Gene Logic¿s Gene Express reference database of normal gene expression profiles; Gene Logic gets $3M/year for 5 years to develop gene expression database for renal disease; Gene Logic gets $17.5M if Japan Tobacco uses its flow-through Gene Chip technology; Japan Tobacco has 2-yearoptions to expand collaboration into 2 other disease areas; Japan Tobacco will buy $3M equity in Gene Logic¿s IPO; if Japan Tobacco opts for all 3 disease areas, Gene Logic gets $100.5M; Japan Tobacco has rights to all small molecule drugs and therapeutic antibodies and proteins; Gene Logic retains rights to gene therapy, antisense and diagnostic products; Gene Logic gets royalties (9/97)

Gene Logic Inc.

The Procter & Gamble Co. (NYSE:PG)

Collaboration to discover targets for new drug development in heart failure via Gene Logic¿s Accelerated Target Discovery platform to analyze gene expression and regulation in heart tissue

$75M

Procter & Gamble will provide $12M in research support and database access fees for heart failure indication (of the $12M, $3M is initial cash payment) and $13M in milestones; Procter & Gamble can expand alliance to include two more disease indications; Gene Logic could get $25M for each of those too; Procter & Gamble has worldwide rights to all therapeutic and diagnostic applications in the heart failure indication; Gene Logic gets royalties (6/97)

Genetics Institute Inc. (wholly owned subsidiary of American Home Products Corp.; NYSE:AHP)

Bayer Corp. (unit of Bayer AG; Germany)

Functional genomics agreement; subscription to Genetics Institute¿s DiscoverEase protein development platform (library of human secreted proteins and related database)

ND

Bayer gets access to Genetics Institute¿s library and database; Bayer will pay small up-front fee on pay-as-go basis; if it selects an individual protein to develop, it will take exclusive license; Genetics Institute retains option to codevelop and co-commercialize product (8/97)

Genetics Institute Inc. (wholly owned subsidiary of American Home Products Corp.; NYSE:AHP)

Chugai Pharmaceutical Co. Ltd. (Japan)

Functional genomics agreement; subscription to Genetics Institute¿s DiscoverEase protein development platform (library of human secreted proteins and related database)

ND

Chugai gets access to Genetics Institute¿s library of expressed human secreted proteins, their corresponding cDNAs and a companion database; futher details ND, but similar terms to other subscriptions (Chugai is 6th subscriber) (10/97)

Genetics Institute Inc. (wholly owned subsidiary of American Home Products Corp.; NYSE:AHP)

Kirin Brewery Inc. (Japan)

Functional genomics agreement; subscription to Genetics Institute¿s DiscoverEase protein development platform (library of human secreted proteins and related database)

ND

Kirin gets access to Genetics Institute¿s library and database; Kirin will pay small up-front fee on payas-go basis; if it selects an individual protein to develop, it will take exclusive license; Genetics Institute retains option to co-develop and co-commercialize product (3/97)

Genetics Institute Inc. (wholly owned subsidiary of American Home Products Corp.; NYSE:AHP)

Pharmacia & Upjohn Inc. (NYSE:PNU; U.K.)

Genetics Institute purchased rights to ReFacto (recombinant Factor VIII) for treating hemophilia A (currently in international Phase III trials)

ND

Genetics Institute will continue clinical development, register and market product; Pharmacia & Upjohn will perform certain development activities and will manufacture product; Pharmacia & Upjohn gets co-promotion rights in Nordic area and the Middle East; financial terms ND (8/97)

Genome Therapeutics Corp.

Bayer AG (Germany)

Subscription to microbial genomics database PathoGenome (contains sequence information on at least 12 pathogens)

ND

Bayer gets non-exclusive access to database; terms include annual subscription fees and royalties on any small molecules developed as result; Genome Therapeutics retains all rights associated with therapeutic, diagnostic and vaccine uses of bacterial genes or gene products (5/97)

Genome Therapeutics Corp.

Bristol-Myers Squibb Co. (NYSE:BMY)

Subscription to microbial genomics database PathoGenome (contains sequence information on at least 12 pathogens)

ND

Bristol-Myers gets non-exclusive access to database; terms include annual subscription fees and royalties on any small molecules developed as result; Genome Therapeutics retains all rights to therapeutic, diagnostic and vaccine use of bacterial genes or gene products (9/97)

Genome Therapeutics Corp.

Schering-Plough Corp. (NYSE:SGP)

Research collaboration; use of functional genomics and other technologies (bioinformatics; highthroughput sequencing) to discover and develop antifungal drugs (especially for Candida albicans and Aspergillus fumigatus infections); separate agreement covers subscription to Genome Therapeutics¿ PathoGenome Database

$33M

Schering-Plough gets exclusive access to genomic information regarding C. albicans and A. fumigatus; Genome Therapeutics retains certain rights to vaccines, diagnostics and plant products; Schering-Plough will pay $33M in research support and milestones as well as royalties; concerning the database subscription, ScheringPlough will pay subscription fees and royalties on any small molecule drugs; Genome Therapeutics retains certain rights to use bacterial genes or gene products as therapeutics, diagnostics and vaccines; it may also get milestones (9/97)

Genset SA (France)

Abbott Laboratories (NYSE:ABT)

Strategic alliance in pharmacogenomics; Genset will develop high-density, biallelic marker map of human genome and will identify markers and genes associated with efficacy and side effects of drugs; Abbott will develop, produce and market clinical diagnostic systems derived from genes and markers

$42.5M (5 0.000000e+00quity)

Abbott will buy $20M in Genset equity ($10M up-front and $10M on exercise of a put option by Genset during 2nd year); as part of an R&D alliance between the parties (on an Abbott compound), Abbott will pay $22.5M in R&D funds and milestones over 18 months; Genset gets royalties on sales of drug and related diagnostic assay; the parties also formed an alliance under which they will collaborate with 3rd parties (under which each will share revenues from milestones and royalties and Genset gets royalties on Abbott¿s sale of diagnostics) (7/97)

Gensia Sicor Inc.

Sankyo Co. Ltd. (Japan)

Research collaboration on drugs for treating Type II diabetes; focus on low molecular weight purine nucleotide analogues that regulate target enzyme (a ratelimiting enzyme in gluconeogenesis pathway)

ND (includes equity)

Sankyo will pay license fees, make undisclosed equity investment and fund research over 3 years; Gensia Sicor also gets milestones and royalties; Sankyo gets exclusive worldwide rights to all products; Gensia Sicor gets co-promotion rights in North America; this collaboration is part of Gensia Sicor¿s transfer of its pharmaceutical R&D into new subsidiary Metabasis Therapeutics Inc. (4/97)

GenVec Inc.*

Parke-Davis (division of WarnerLambert Co.; NYSE:WLA)

Collaboration on gene therapy for heart disease; development of GenVec¿s BioByPass product (delivers vascular endothelial growth factor [VEGF] gene in adenoviral vector to heart to induce new blood vessel formation in ischemic tissues)

$100M (equity; % ND)

GenVec could get $100M in precommercialization payments; specifics ND but involves up-front cash payment, R&D funding and milestones over 5 years; ParkeDavis will also buy equity in several tranches, including at the time of GenVec¿s IPO; Parke-Davis gets marketing rights worldwide except in Asia for BioByPass and related products; GenVec gets royalties and retains certain manufacturing and co-promotion rights (9/97)

Genzyme Corp.

Bayer AG (Germany)

Drug discovery agreement; use of Genzyme¿s library of over 1 million small molecules to identify new drug candidates for undisclosed disease targets

$35M

Bayer will pay undisclosed up-front fee to access Genzyme¿s library; Bayer will analyze small molecule leads with its high-speed robotic screens; when it selects development candidates, Genzyme gets milestones as compounds proceed through clinical trials (12/97)

Genzyme Molecular Oncology (division of Genzyme Corp.)

Parke-Davis (division of WarnerLambert Co.; NYSE:WLA)

Genomics collaboration; service and license option agreement on use of Genzyme Molecular¿s SAGE technology (serial analysis of gene expression) in pharmacogenomic profiling (changes in gene expression in tissues following exposure to drug candidates)

$9M

If Parke-Davis exercises option to take non-exclusive license on SAGE technology for use in its internal genomics research programs, it will pay Genzyme Molecular $9M in service and license fees (11/97)

Genzyme Transgenics Corp.

B. Braun Melsungen AG (Germany)

Agreement to develop transgenic form of undisclosed recombinant therapeutic product (2nd generation, i.e. transgeneric) via milk of transgenic goats

$13M

Genzyme Transgenics will express product in milk of transgenic goats, make clinical-grade product and conduct preclinical and early clinical studies; it gets $13M in milestones; partners will share worldwide responsibility for pivotal trials; Braun gets exclusive worldwide marketing rights; Genzyme Transgenics retains certain marketing rights in North America (9/97)

Genzyme Transgenics Corp.

BASF Bioresearch Corp.

Agreement to produce undisclosed biopharmaceuticals in milk of transgenic goats

$6M

BASF will pay up to $6M in R&D support and milestones over 3 years; agreement contains provisions for Genzyme Transgenics to provide commercial supply of products (once approved) (1/97)

Genzyme Transgenics Corp.

Bristol-Myers Squibb Co. (NYSE:BMY)

Agreement to develop humanized monoclonal antibody CTLA41g in milk of transgenic goats; antibody blocks T cell stimulation (currently in Phase II trial for psoriasis but other indications include organ transplant rejection and autoimmune disorders)

ND

This is 2nd agreement between the firms; after development phase, they will sign commercialization agreement for scale-up, manufacturing and marketing; further details ND (9/97)

Genzyme Transgenics Corp.

Fresenius AG (Germany)

Agreement to develop and commercialize transgenic human serum albumin (produced in milk of cows)

$17M

Fresenius will pay $17M in initial fees, development funds, milestones and option payments; Fresenius will conduct all product development and marketing; after product approval, Genzyme Transgenics will provide product at a transfer price and get royalties (3/97)

Geron Corp.

Boehringer Mannheim GmbH (Germany)

Collaboration on in vitro cancer diagnostics; use of Geron¿s technologies for detecting and measuring telomerase expression and level of activity (correlates with presence and severity of many cancers)

ND

Geron gets funding and milestones; Boehringer Mannheim is responsible for all preclinical and clinical product development; Boehringer Mannheim gets exclusive worldwide marketing rights; Geron gets royalties; Geron retains co-promotion rights in U.S. (12/97)

Glyko Biomedical Ltd. (TSE:GBL)

Array Medical Inc.

Agreement to jointly develop diagnostic point-of-care test for measuring heparin (during surgical and medical procedures) via Glyko¿s fluorescence detection technology

ND

Array will fund product development and market device worldwide (4/97)

Houghten Pharmaceuticals Inc. (now known as Trega Biosciences Inc.)

Chugai Biopharmaceuticals Inc. (subsidiary of Chugai Pharmaceutical Co. Ltd.; Japan)

Drug discovery collaboration and license agreement to use Houghten¿s combinatorial chemistry libraries to identify drug candidates for treating bone, cardiovascular and infectious disease targets; Houghten obtained biological targets in diabetes and central nervous system disorders

ND

Chugai gets nonexclusive rights to screen Houghten¿s libraries for drug candidates; Chugai gets rights to products in its fields; Houghten gets up-front fees, milestones and royalties; in target area of inflammation, companies will jointly develop and commercialize products; for targets in Houghten¿s areas, Houghten will develop and commercialize and Chugai gets royalties (1/97)

Human Genome Sciences Inc.

SmithKline Beecham plc (NYSE: SBH; U.K.)

New agreement to streamline procedures of original 5/93 agreement regarding diagnostic applications of Human Genome¿s human gene technology

ND

New agreement simplifies procedures by which SmithKline can outlicense diagnostic products based on Human Genome¿s technology; also, Human Genome can now develop and market diagnostics for its own therapeutic products; Human Genome can outlicense diagnostics for drugs that it outlicenses; Human Genome gets royalties on diagnostics created with its technology and outlicensed by SmithKline (7/97)

Hyseq Inc.

The Perkin-Elmer Corp. (NYSE:PKN)

Collaboration to accelerate development of Hyseq¿s DNA HyChip technology by combining it with Perkin-Elmer¿s DNA analysis technologies; goal is to create a universal chip that can assay any genetic target

$10M (>5 0.000000e+00quity)

Perkin-Elmer has bought $5M in Hyseq equity and will buy additional $5M concurrent with Hyseq¿s IPO (giving it >5take total); both companies will invest in product development; PerkinElmer gets exclusive worldwide rights to commercialize sequencing systems using HyChip technology; collaboration has initial term of 5 years (6/97)

ICAgen Inc.*

Abbott Laboratories (NYSE:ABT)

Research collaboration on small molecule drugs for treating selected central nervous system and urological disorders; use of ICAgen¿s ion channel molecular targets and its gene family chemical libraries to generate selected ion channel targets

$12M

3-year collaboration with options for renewal; ICAgen gets $12M up-front plus milestones and royalties; Abbott will screen compounds, optimize lead candidates and perform all phases of product development (12/97)

ICAgen Inc.*

Bristol-Myers Squibb Co. (NYSE:BMY)

Collaboration on small molecule drugs targeting ion channels involved in atrial fibrillation (irregular heartbeat)

$75M

2-year agreement with option to extend to 3rd year; ICAgen gets initial up-front payment, research funding and milestones (for total $75M); Bristol-Myers gets exclusive worldwide rights to lead compounds for treating atrial fibrillation and will conduct all product development; ICAgen gets royalties (9/97)

Icos Corp.

Suntory Ltd. (Japan)

Agreement to form joint venture company, called Suncos Corp., to develop and commercialize recombinant platelet activating factor acetylhydrolase (rPAF-AH) for treating certain inflammatory diseases

$30M

Suntory will contribute $30M in initial capital for joint venture; Icos licensed rPAF-AH technology to Suncos; both ¿parents¿ will jointly fund all development activities and expenses; Icos will market product in U.S.; Suntory has rights in Japan; Suncos gets royalties from each parent; Suncos has marketing rights elsewhere (1/97)

Idec Pharmaceuticals Corp.

Boehringer Ingelheim GmbH (Germany)

Licensing agreement on Idec¿s vector technology for high expression of recombinant proteins in mammalian cells

ND

Idec will get licensing fees and royalties; further details ND (1/97)

Idec Pharmaceuticals Corp.

Kirin Brewery Co. Ltd. (Japan)

License on Idec¿s vector technology for high expression of recombinant proteins in mammalian cells

$6.3M

Idec gets up-front licensing fee of $6.3M plus royalties; Kirin is 4th and final licensee for this particular platform technology (12/97)

Idec Pharmaceuticals Corp.

Pharmacia & Upjohn Inc. (NYSE:PNU)

Idec acquired rights to 9-AC (9-aminocamptothecin), a broad-spectrum small-molecule anticancer drug (it is in Phase II trials in various tumor types); the drug is a semi-synthetic analogue of the plant-derived molecule camptothecin (which interferes with DNA replication by inhibiting topoisomerase I)

$3M

Idec acquired worldwide rights to 9-AC; Idec will pay Pharmacia & Upjohn $3M initially plus milestones but no royalties (the Federal Trade Commission required this divestiture in 10/95 as part of the merger of Pharmacia with Upjohn); the FTC must also approve Idec¿s acquisition of 9-AC (preliminary agreement 2/97; Federal Trade Commission approved transaction 7/97)

Ilex Oncology Inc. and Physician Reliance Network Inc.

Eli Lilly & Co. (NYSE:LLY)

Agreement to develop 2 of Lilly¿s anticancer compounds in the clinic (one is in Phase II, the other is in Phase I, both in solid malignant tumors)

ND

5-year agreement; as part of this, the Cancer Therapy and Research Center (CTRC) Research Foundation will conduct preclinical and clinical research; Ilex will serve as CRO and manage the clinical development of both drugs; other parties will participate in trial design and serve as research trial sites (5/97)

ImmuCell Corp.

Murray Goulburn Co-Operative Co. Ltd. (Australia)

Licensing agreement on ImmuCell¿s milk purification technology for use in manufacturing of whey protein isolate (food additive)

$0.3M

License excludes rights to produce lactoferrin or immunoglobulins; ImmuCell gets royalties (11/97)

Incyte Pharmaceuticals Inc.

Bristol-Myers Squibb Co. (NYSE:BMY)

Genomic database agreement for access to Incyte¿s LifeSeq gene sequence and gene expression database

ND

Bristol-Myers gets access to certain of Incyte¿s databases and will pay yearly access fee; Incyte could get milestones and royalties on products that result (3/97)

Incyte Pharmaceuticals Inc.

Glaxo Wellcome plc (NYSE:GLX; U.K.)

Genomic database partnership; Glaxo gets access to specific LifeSeq database products at 8 worldwide research sites

ND

Multiyear agreement; Incyte gets annual access fees and royalties; details of specific products licensed ND (5/97)

Incyte Pharmaceuticals Inc.

Novartis AG (Switzerland)

Incyte will develop an enterprise-wide bioinformatics software and data management system to support Novartis¿ global research efforts (based on LifeTools suite of bioinformatics software)

ND

ND (6/97)

Incyte Pharmaceuticals Inc.

NV Organon (unit of Akzo Nobel; the Netherlands)

Genomic database agreement for access to Incyte¿s LifeSeq gene sequence and expression database and LifeSeq GeneAlbum reagent set

ND

Multiyear agreement; Organon gets non-exclusive access to data base in exchange for annual fees; Incyte could get royalties on products that Organon develops (10/97)

Incyte Pharmaceuticals Inc.

Rhone-Poulenc SA (NYSE:RP; France)

Genomic database agreement for access to Incyte¿s LifeSeq gene sequence and expression database and PathoSeq microbial database

ND

Multiyear agreement; Rhone-Poulenc gets non-exclusive access to database; Incyte gets annual fees and could get milestones and royalties on products that result (12/97)

Incyte Pharmaceuticals Inc.

SmithKline Beecham plc (NYSE: SBH; U.K.)

Formation of joint venture company diaDexus to discover and commercialize molecular diagnostics; links SmithKline¿s genomics/molecular targets (its own and those discovered from its collaboration with Human Genome Sciences) with Incyte¿s human and microbial databases; initially, diagnostics will be for disease detection; will also focus on pharmacogenomics

$25M

SmithKline and Incyte will each own 50 0.000000e+00quity in diaDexus, which has exclusive rights to develop new diagnostics; SmithKline will exclusively license to diaDexus a number of diagnostic tests in late-stage clinical trials; Human Genome Sciences gets royalties from sales of products developed from its technology; diaDexus gets non-exclusive access to Incyte¿s databases as well as its bioinformatics capabilities and GeneJet array technology; partners will each assign additional technologies and patent rights to diaDexus; partners will contribute $25M in funding (9/97)

Incyte Pharmaceuticals Inc.

SmithKline Beecham plc (NYSE: SBH; U.K.)

Microbial database agreement for access to Incyte¿s PathoSeq microbial genome database

ND

Multiyear agreement; SmithKline gets non-exclusive access to database; Incyte gets annual fees and could get milestones and royalties on products that result (9/97)

Inhale Therapeutic Systems

Centeon LLC (joint venture of Hoechst AG and Rhone-Poulenc Rorer Inc.)

Development and licensing agreement on pulmonary formulations of Centeon¿s alpha-1 proteinase inhibitor (for treating alpha-1 antitrypsin deficiency); will use Inhale¿s deep-lung delivery system for macromolecules

$15M

Inhale gets up-front signing fee, R&D funds, milestones and royalties; Centeon gets worldwide rights outside Japan; Centeon will manufacture active ingredient for use in Inhale¿s deep-lung delivery device; Inhale will manufacture and package dry powder and supply inhalation devices to Centeon for marketing (1/97)

Inhale Therapeutic Systems

Eli Lilly & Co. (NYSE:LLY)

Collaboration and licensing agreement to develop pulmonary delivery technology for a selected osteoporosis product; will use Inhale¿s deep-lung delivery system for macromolecules

$20M

Inhale will get $20M in initial fees, research funds and milestones; Lilly gets worldwide rights to commercialize product; Inhale gets royalties; Inhale will manufacture packaged dry powder formulations of drug for Lilly and will also supply inhalation devices; Lilly responsible for further clinical development (1/97)

Innogenetics NV (EASDAQ:INNX; Belgium)

Solvay SA (Belgium)

Research collaboration to discover genes for human diseases, especially heart disease and central nervous system disorders, and to use them as drug development targets

$49.5M (8.3 0.000000e+00quity)

Solvay will buy 8.3 0.000000e+00quity stake for $35.5M (2M shares at $17.75 each); Solvay will also pay $4M up-front and pay $1.5M-$2M for R&D support annually for 5 years; Innogenetics also gets milestones and royalties (11/97)

Interneuron Pharmaceuticals Inc.

Eli Lilly & Co. (NYSE:LLY)

Licensing of use patent on Lilly¿s antidepressant Prozac (fluoxetine HCl; a selective serotonin re-uptake inhibitor)

ND

Interneuron has patent rights (from MIT) for use of product in treating symptoms of pre-menstrual syndrome (PMS); Lilly will sublicense these rights; Interneuron gets up-front fees, milestones and royalties (6/97)

IntraBiotics Pharmaceuticals Inc.*

Pharmacia & Upjohn Inc. (NYSE:PNU; U.K.)

Collaboration on topical anti-microbial compound IB-367 (synthetic peptide based on natural host defense peptide protegrin); drug is currently in Phase I trials for oral mucositis (complication of chemoand radiation therapy)

$35M (equity; % ND)

Companies will co-develop and promote product in U.S.; they will also share profits; Pharmacia gets exclusive license in all other territories; IntraBiotics gets royalties; IntraBiotics gets reimbursed for half of all development expenses and also gets $35M in license fees, milestones and equity; IntraBiotics will manufacture product (10/97)

Karo Bio AB* (Sweden)

Bristol-Myers Squibb Co. (NYSE:BMY)

Collaboration on drugs for treating metabolic disorders (i.e., obesity, hypercholesterolemia) based on thyroid hormone receptor beta (TR beta) agonists (based on Karo Bio¿s 3D structural data)

$40M

3-year collaboration; Karo Bio could get $40M if two therapies developed and approved for marketing; companies will jointly manage research and preclinical development; Bristol-Myers gets worldwide rights to products; Karo Bio gets milestones and royalties (10/97)

Karo Bio AB* (Sweden)

Merck & Co. Inc. (NYSE:MRK)

Strategic alliance on drugs and diagnostics for diseases and conditions that are affected by estrogen receptors (especially via Karo Bio¿s structural data on estrogen receptors alpha and beta)

$80M

Agreement valued at US$80M if Merck develops and gets regulatory approval for 2 compounds as distinct therapies; companies will jointly manage research and preclinical development; Merck gets exclusive worldwide rights to compounds; Karo Bio gets up-front and milestone payments and R&D funding as well as royalties (11/97)

Kimeragen Inc.*

Hoechst Schering AgrEvo GmbH (Germany)

License agreement on use of Kimeragen¿s gene enhancement technology (chimeraplasty) to identify specific plant gene functions in crops and to target specific gene modifications

ND

AgrEvo and its subsidiary Plant Genetic Systems NV get nonexclusive license to technology; further details ND (10/97)

Kimeragen Inc.*

Pioneer Hi-Bred International Inc. (NYSE:PHB)

Research collaboration on use of Kimeragen¿s gene enhancement technology (chimeraplasty) for genetic improvement of crops; 1st target is to develop new seed corn products

ND

Pioneer gets a non-exclusive license to use the chimeraplasty technology (wherein chimeric oligonucleotides are used to produce base pair changes in targeted genes to enhance expression); Pioneer can use technology in any plant species; further details ND (3/97)

LeukoSite Inc.

Becton Dickinson and Co. (and its units Becton Dickinson Immunocytometry Systems and PharMingen; NYSE:BDX)

License on chemokines and receptors for use as research and diagnostic reagents

ND

Becton Dickinson and its units get exclusive worldwide license to commercialize antibodies to several chemokines and chemokine receptors (including CCR5, the co-receptor for HIV) for research use; companies have option to develop in vitro diagnostics (10/97)

Ligand Pharmaceuticals Inc.

Eli Lilly & Co. (NYSE:LLY)

Strategic alliance on products for treating diabetes and additional metabolic diseases; based on Ligand¿s intracellular receptor technology, i.e. retinoid X receptor (RXR) agonists including oral Targretin (currently in Phase II European trials for treating Type II diabetes)

$194M (equity; % ND)

Ligand gets $49M in research funding over 5 years plus possible extra 3 years of research funding, $37.5M in equity investment (at premium to market), $12.5M in up-front milestones, $75M in additional milestones over 8 years for successful development of oral Targretin and 5 other compounds and royalties; Ligand also gets its choice of either rights to one of Lilly¿s niche cancer products or an additional $20M equity investment; Ligand also gets milestones, royalties and options to certain co-development rights for a Lilly-selected RXR compound in combination with a selective estrogen receptor modulator (SERM); Lilly gets rights to oral Targretin, exclusive rights to 2nd generation oral diabetes compounds, exclusive rights to Ligand¿s metabolic disease technology; additional rights to use technology to develop a compound in combination with SERM for treating cancer; closing subject to completion of Ligand¿s buyback of Allergan Ligand Retinoid Therapeutics (ALRT) shares and restructured rights to AL

MacroChem Corp. and Cytopharm Inc.*

Glaxo Wellcome plc (NYSE:GLX; U.K.)

Licensing agreement on MacroChem¿s SEPA transdermal enhancer technology for use with Cytopharm¿s porphyrin compound for photo-dynamic therapy of psoriasis and other skin diseases

ND

MacroChem had previously licensed SEPA to Cytopharm for topical formulation of porphyrin compound (which resulted from research performed by Glaxo); Glaxo sublicensed the technology; further details ND (5/97)

Magainin Pharmaceuticals Inc.

SmithKline Beecham plc (NYSE:SBH; U.K.)

Development and marketing agreement on Cytolex (MSI-78) broadspectrum topical antibiotic cream for treating infections in diabetic foot ulcers (MSI-78 is analogue of natural host-defense peptide isolated from frogs) (in two Phase III trials)

$32M

Magainin will get $5M up-front and $27.5M for milestones; SmithKline will fund part of developmest cost for additional indications for Cytolex; SmithKline has option to negotiate for rights to another product development candidate; SmithKline gets North American marketing rights; Magainin gets royalties; Magainin will supply commercial product to SmithKline; Magainin retained rights outside North America (2/97)

MediGene AG* (Germany)

Hoechst Marion Roussel Inc. (subsidiary of Hoechst AG; Germany)

Collaboration on viral vectors for gene therapy, especially MediGene¿s recombinant adeno-associated virus (AAV) vector technology for ex vivo tumor vaccination in melanoma

$5.8M

3-year collaboration; MediGene will conduct Phase I and II trials in melanoma; companies have option of extending collaboration to include other indications; Hoechst Marion will fund research and make GMP-quality vectors; collaboration is co-sponsored by the Bavarian Science Foundation; total value $5.8M (DM10M; converted at ratio of 1.73DM/US$1) (11/97)

MedImmune Inc.

SmithKline Beecham plc (NYSE: SBH; U.K.)

Strategic alliance to develop human papillomavirus (HPV) vaccines for preventing cervical cancer and genital warts; vaccines based on MedImmune¿s virus-like particle technology for making noninfectious form of virus; 1st candidate MEDI-501 (HPV-11) currently in Phase I trials

$85M

MedImmune gets up-front payment, research funding and milestones totaling $85M; SmithKline gets exclusive worldwide rights to vaccine technology; companies will collaborate on R&D; MedImmune will conduct Phase I and II trials and manufacture clinical material; SmithKline will then take over final product development, manufacturing, regulatory submissions and marketing; MedImmune gets royalties; agreement subject to clearance under antitrust law (12/97)

Megabios Corp.

Eli Lilly & Co. (NYSE:LLY)

Collaboration on a gene-based therapeutic for certain solid tumors; focus is on a single gene to be delivered via lipid-based system

ND (includes equity)

Lilly gets worldwide rights to product; Lilly will buy equity stake in Megabios, fund research for 4 years and pay milestones and royalties; Megabios will develop a gene delivery system and share responsibility with Lilly for preclinical development; Lilly responsible for all further development and commercialization (5/97)

Mendel Biotechnology Inc.*

Monsanto Co. (NYSE:MTC) and Empresas La Moderna SA (ELM; Mexico)

Broad-based collaboration in agricultural functional genomics; use of Mendel¿s technical capabilities in plant genetics and genomics for improving agricultural traits of seeds and crops

ND (includes equity)

Monsanto/ELM get exclusive access to Mendel¿s technology; Monsanto/ELM will each acquire substantial minority equity stake in Mendel and fund R&D over 5 years; further details ND (11/97)

Metabolex Inc.*

Abbott Laboratories (NYSE:ABT)

Two R&D and licensing agreements on products for treating diabetes: 1) drug development via Metabolex¿s intracellular glucose transport signal transduction pathway and insulin resistance program and 2) use of orally active insulin potentiating factor (IPF) as ingredient in nutritional products for diabetics

$4M (<5 0.000000e+00quity)

Abbott made $4M equity investment (simultaneously Metabolex obtained $29.5M in private financing); Metabolex will identify molecular targets involved in method of insulin resistance and develop screening assays based on them; Abbott will screen its compound libraries and synthesize analogues; Abbott has exclusive worldwide rights and is responsible for all development and commercialization; Metabolex gets milestones and royalties; Abbott also has exclusive rights to use IPF in nutritional products (6/97)

Microcide Pharmaceuticals Inc.

Daiichi Pharmaceutical Co. Ltd. (Japan)

Microcide will provide Daiichi with subset of its synthetic molecular diversity collection to use in the latter¿s drug discovery screening programs

$1.5M

Microcide will get $1.5M for supplying compounds (6/97)

Millennium BioTherapeutics Inc. (MBIO; majorityowned subsidiary of Millennium Pharmaceuticals Inc.)

Eli Lilly & Co. (NYSE:LLY)

Genomics-based therapeutic protein discovery collaboration

$70M (18 0.000000e+00quity)

3-year program; Lilly will pay $8M-$10M/year to support research; if the parties extend collaboration for 2 more years, Lilly will fund those at same level; Lilly will also pay licensing fees, milestones and royalties in connection with specific therapeutic protein candidates; Lilly will also buy $20M of equity in Millennium BioTherapeutics for 18take; each partner has equal rights to select candidate therapeutic proteins for exclusive development; both companies will share right to use any discoveries to develop small molecule drugs; Millennium BioTherapeutics retains right to use discoveries for all other purposes (antibody therapy, gene therapy and antisense products) (5/97)

Millennium Pharmaceuticals Inc.

Monsanto Co. (NYSE:MTC)

Broad collaboration in genomics; use of Millennium¿s technologies to discover and develop genomics-based plant and agricultural products

$218M

Five-year agreement; Monsanto will form wholly owned subsidiary in Cambridge, Mass. as part of deal; Millennium will non-exclusively license and transfer to Monsanto genomics technologies for use in R&D of life sciences products (including pharmaceuticals); Millennium gets $118M in up-front licensing and technology transfer fees ($38M in 1997 and $20M annual for 4 more years); Millennium also gets $100M over 5 years for milestones; Monsanto will fund R&D at its new subsidiary; Millennium gets royalties on certain plant and animal products; Millennium has rights to use certain technologies developed by new company for nonexclusive use outside plant and agricultural areas; collaboration subject to antitrust clearance (10/97)

Molecular Dynamics Inc. and Amersham International plc (U.K.)

DuPont Agricultural Products (division of E.I. Du Pont de Nemours and Co.; NYSE:DD)

Technology access agreement; to further develop high throughput DNA microarray technologies

ND

DuPont will use microarray system to study gene expression levels in agricultural seed and plant species and to accelerate development of products with greater plant health disease resistance; DuPont will provide funding and collaborative expertise in exchange for early access to latest microarray technologies (10/97)

Molecular Dynamics Inc. and Amersham plc (U.K.)

Zeneca Ltd. (NYSE:ZEN; U.K.)

Technology access agreement; to further develop high-throughput ation and reagents for gene analysis

ND

Zeneca is 1st partner in Molecular Dynamics/Amersham¿s Microarray Technology Access programInternationalmicroarray instrument-Zeneca will provide funding and expertise in exchange for early access to latest DNA microarray technologies (5/97)

Molecular Simulations Inc.*

Bayer Corp. (subsidiary of Bayer AG; Germany)

Bayer has become a founding member of Molecular Simulations¿ Combinatorial Chemistry Consortium

ND

3-year agreement; Bayer will help set scientific directions of newly developed products for library comparison, combinatorial selection and various library focusing techniques (4/97)

Molecular Simulations Inc.*

Glaxo Wellcome plc (NYSE:GLX; U.K.)

Glaxo has become a founding member of Molecular Simulations¿ Combinatorial Chemistry Consortium

ND

3-year agreement; Glaxo will help extend state-of-art in combinatorial chemistry software as applied to drug discovery and lead optimization; Glaxo has licensed the software for use in its facilities worldwide (6/97)

Molecular Simulations Inc.*

Monsanto Co. (NYSE:MTC)

Monsanto (including its G.D. Searle & Co. unit) has become member of Molecular Simulations¿ Combinatorial Chemistry Consortium

ND

Details ND (12/97)

Molecumetics Ltd. (subsidiary of Tredegar Industries; NYSE:TG)

Asahi Chemical Industry Co. Ltd. (Japan)

Research collaboration on use of Molecumetics¿ SMART library technology (combines combinatorial chemistry and structural biology) to discover and develop orally active inhibitors of Factor VIIa (for treating blood clotting disorders)

ND

Molecumetics will identify and optimize compounds; Asahi is responsible for preclinical and clinical development of drugs in Japan and other Asian countries; Molecumetics gets research funding, milestones and royalties; Molecumetics retains all rights in U.S. and Europe (5/97)

Molecumetics Ltd. (subsidiary of Tredegar Industries; NYSE:TG)

Teijin Ltd. (Japan)

Research and licensing collaboration on use of Molecumetics¿ orally active thrombin inhibitors to develop drugs for blood clotting disorders

ND

Molecumetics will optimize drug leads; both firms will do preclinical studies; Teijin responsible for clinical and regulatory work; Teijin will market in Japan and other Asian areas; Molecumetics retains rights in U.S. and Europe; Molecumetics gets initial fees, research funds, milestones and royalties (9/97)

MorphoSys GmbH* (Germany)

Pharmacia & Upjohn Inc. (NYSE:PNU; U.K.)

Research collaboration to use MorphoSys¿ HuCAL (human antibody library) and SIP (phage-based screening) technologies to accelerate discovery, optimization and production of therapeutically active peptides and proteins; also for analysis of gene function in genomics research

$50M (equity; % ND)

6-year agreement; Pharmacia & Upjohn will buy $2.5M in equity now and another $2.5M at the IPO; for 1st 2 years, MorphoSys will get $5.5M in technology access fees and R&D funds; thereafter, it will get $8M license fee to apply technologies to specific targets and $12M for R&D; MorphoSys also gets milestones on therapeutic development and on use of targets; Pharmacia & Upjohn has exclusive rights to commercialize products; MorphoSys gets royalties (3/97)

Myriad Genetics Inc.

Bayer Corp. (subsidiary of Bayer AG; Germany)

Research collaboration to discover gene targets and develop drugs for treating dementia and depression via Myriad¿s positional cloning and ProNet technology (protein interaction network; database of human proteins and their biochemical pathways)

$54M

Bayer is 1st pharmaceutical company to license ProNet database; Myriad gets $54M in research and milestone payments; Myriad will use its database of Utah families to identify genes of interest; 5-year collaboration; Bayer gets worldwide therapeutic rights for discoveries in dementia and depression; Myriad retains rights to diagnostics in those areas and all rights outside those fields (11/97)

Myriad Genetics Inc.

Schering-Plough Corp. (NYSE:SGP)

Strategic agreement to discover genes and develop therapies for prostate and other cancers (including brain, skin, breast and kidney)

$60M (equity; % ND)

Schering-Plough gets exclusive worldwide rights to all pharmaceuticals; Myriad retains rights to all diagnostic products and services and gets royalties on sales of drugs; 3-year research program that may be extended for 2 additional 1-year periods; for full 5 years and 5 target genes, Myriad would get $60M total; ScheringPlough made undisclosed equity investment and will also fund R&D and pay for milestones (4/97)

Nanogen Inc. (IPO pending)

Becton, Dickinson and Co. (NYSE: BDX)

Joint venture to develop in vitro nucleic acidbased diagnostic and monitoring technologies via Nanogen¿s DNA microchip and instrumentation technology and Becton, Dickinson¿s Strand Displacement Amplification technology

$55M (equity; % ND)

Both companies will fund research and product development, manufacturing and product promotion; Becton, Dickinson will contribute total of $55M in funds and equity investment and will buy additional equity in Nanogen¿s IPO; Nanogen gets license to Becton, Dickinson¿s DNA amplification technology; this joint venture supercedes the R&D collaboration the companies formed in 5/97 (10/97)

NanoSystems LLC*

Astra Draco AB (unit of Astra AB; Sweden)

Collaboration to develop new formulations of certain Astra products for treating respiratory disorders via NanoCrystal formulation (makes nanoparticles)

ND

NanoSystems will get up-front license fee, research funds, milestones and manufacturing fees based on product sales; further terms ND (3/97)

NanoSystems LLC*

Merck & Co. Inc. (NYSE:MRK)

Collaboration and license agreement on use of NanoCrystal drug formulation technology to develop nanoparticle formulation of Merck drug

ND

This is 2nd agreement between the parties; NanoSystems gets up-front license fee, research and milestone payments, supply fee and royalties (6/97)

NanoSystems LLC*

Parke-Davis (division of Warner-Lambert Co.; NYSE: WLA)

Collaboration and licensing agreement on use of NanoCrystal drug formulation technology to develop nanoparticle formulation of ParkeDavis compound (used for drugs with low solubility in water)

ND

3-year agreement; NanoSystems gets R&D funding, milestone payments and royalties (4/97)

NanoSystems LLC*

Rhone-Poulenc Rorer Inc. (subsidiary of RhonePoulenc Group; NYSE: RP; France)

Feasibility study to evaluate new formulations of RPR¿s asthma drug triamcinolone acetonide (respiratory steroid) made via NanoCrystal technology (for delivery of poorly water-soluble drugs)

ND

Rhone-Poulenc Rorer has exclusive option to license technology; further details ND (12/97)

NanoSystems LLC*

Wyeth-Ayerst Laboratories (division of American Home Products Corp.; NYSE:AHP)

Collaboration and licensing agreement on use of NanoCrystal drug formulation technology to develop nanoparticle formulation of WyethAyerst¿s immunosuppressant Rapamune (which will be evaluated in late-stage clinical trials)

ND

NanoSystems will get up-front license fee, research payments and royalties; further terms ND (5/97)

NaviCyte Inc.*

SmithKline Beecham plc (NYSE: SBH; U.K.)

Collaboration on use of NaviCyte¿s computational biology tools to identify new candidates for drug development (IDEA simulation software enables prediction of drug¿s pharmacokinetic outcome in humans)

ND

SmithKline will provide data and make initial and milestone payments; SmithKline gets license to software and computational models for use with its compound libraries (11/97)

NemaPharm Inc. (wholly owned subsidiary of Sequana Therapeutics Inc.)

Glaxo Wellcome plc (NYSE:GLX; U.K.)

Functional genomics drug discovery alliance; use of NemaPharm¿s animal model system (the nematode worm Caenorhabditis elegans) to evaluate function of certain unidentified human genes and then identify targets for drug discovery

ND

Glaxo Wellcome will fund all research and pay milestones based on NemaPharm¿s identification of targets that become part of Glaxo Wellcome¿s drug discovery programs; Sequana/NemaPharm will get future royalties; financial terms ND (1/97)

NeoRx Corp.

Janssen Pharmaceutica NV (Belgium; unit of Johnson & Johnson; NYSE:JNJ)

Strategic alliance on NeoRx¿s Avicidin cancer therapy (radioimmunotherapy product; currently in Phase I/II clinical trials for solid tumors) (uses NeoRx¿s pretargeting technology)

$60M (equity; % ND)

NeoRx gets $10M up-front ($5M of which is equity) and gets another $50M for milestones; Johnson & Johnson Development Corp. will buy $5M of convertible preferred stock that converts to common at $6/share (before 8/98) and at market afterwards; Johnson & Johnson gets worldwide exclusive license to Avicidin and right of 1st negotiation on subsequent oncology products using same technology, but NeoRx has retained rights to technology per se; Janssen will be responsible for product registration and commercialization and will fund 950f remaining costs for product development and trials; NeoRx retains right to co-promote product in U.S. (8/97)

NeoRx Corp.

Schwarz Pharma AG (Germany)

Agreement to develop Biostent (combination drug/device, whose active ingredient is cytocholasin B) for treating restenosis following balloon angioplasty (Phase I trial completed)

$60M (equity; % ND)

Schwarz Pharma gets marketing rights in North America and Europe; Schwarz Pharma will fund all future product development; NeoRx retains worldwide manufacturing rights and marketing rights for all other territories; NeoRx gets $30M in license fees and milestones (initial payment of $8M includes $4M in equity at 500remium to market); Schwarz Pharma will also pay $30M for future development; NeoRx also gets fees on sales and profits from manufacturing (4/97)

Neose Technologies Inc.

McNeil Specialty Products Co. (subsidiary of Johnson & Johnson; NYSE:JNJ)

Joint program to develop commercially practical, large-scale enzymatic manufacturing process for certain naturally occurring oligosaccharides for human healthcare applications

ND

ND (11/97)

NetGenics Inc.*

Abbott Laboratories (NYSE:ABT)

Use of NetGenics¿ Synergy software and services to manage data generated by Abbott¿s genomics research program

ND

Renewable 3-year agreement; NetGenics will tailor Synergy for use with Abbott¿s data; financial terms ND (12/97)

Nova Molecular Inc.* (Canada)

Amersham Pharmacia Biotech Ltd. (Sweden)

Option agreement on sequencing project to identify unique gene variants in 4 specific central nervous system-related genes (pharmacogenomics study to identify responders and non-responders to certain drugs)

ND (includes equity)

Amersham Pharmacia will make undisclosed equity investment in Nova Molecular; Amersham Pharmacia gets right to research market applications of DNA analysis-related discoveries from this project (10/97)

Oncogene Science Inc. (now known as OSI Pharmaceuticals Inc.)

The Dow Chemical Co. (NYSE:DOW)

Licensing agreement on Dow¿s 140,000-compound library; Oncogene will screen the compounds against drug targets in its internal and collaborative drug development programs

ND

Oncogene Science gets exclusive worldwide license to Dow¿s library and will own rights to most of the drugs it may develop from resulting leads; Dow will get 0.35M shares of Oncogene stock (which Oncogene repurchased from Becton Dickinson and Co. in a separate and prior transaction) (3/97)

Oncogene Science Inc. (now known as OSI Pharmaceuticals Inc.)

Hoechst Marion Roussel Inc. (subsidiary of Hoechst AG; Germany)

Collaborative research and license agreement to develop orally active small molecule inducers of erythropoietin gene expression; for treating anemia due to chronic renal failure or associated with chemotherapy in AIDS and cancer patients

$30M

Oncogene will gets $30M in research funds and success fees, as well as royalties; Hoechst Marion Roussel responsible for all clinical development (3/97)

Oncogene Science Inc. (now known as OSI Pharmaceuticals Inc.)

Sankyo Co. Ltd. (Japan)

Collaborative research and license agreement on small-molecule drugs for treating influenza; Oncogene will identify lead compounds (which interfere with viral replication) from its natural product and medicinal chemistry libraries

ND

Oncogene and its academic partner U.K.-based MRC Collaborative Center, will get license fees, research funds, milestones and royalties; Sankyo gets exclusive world wide rights to all products (3/97)

Oncogene Science Inc. and Cold Spring Harbor Laboratory

Roche Holding Ltd. (Switzerland)

Formation of new company Helicon Therapeutics Inc. to discover, develop and commercialize drugs for treating longterm memory disorders and other central nervous system dysfunctions; based on CREB gene family of transcription factors that control synthesis of proteins required for long-term memory

ND

All parties, including scientists and others at Cold Spring Harbor, will own Helicon; Oncogene Science will screen Roche¿s chemicalcal compounds in its human cell assays to identify compounds that regulate transcription of CREB gene; Cold Spring Harbor will contribute genetics; Roche will fund research and contribute capital as well as provide its expertise in central nervous system research (7/97)

OncorMed Inc.

RPR Gencell (division of RhonePoulenc Rorer Inc.) and its partner Introgen Therapeutics Inc.*

OncorMed will conduct p53 testing for RPR Gencell/Introgen¿s Phase I and II clinical trials of adenoviral p53 gene therapy (in head and neck cancer)

ND

Details ND (9/97)

Onyx Pharmaceuticals Inc.

Parke-Davis (division of Warner-Lambert Co.; NYSE:WLA)

R&D collaboration on drugs that inhibit the intracellular enzymes and other proteins that lead to inflammation and autoimmune disorders

$30M

3-year collaboration; total precommercialization payments to Onyx could exceed $30M; Onyx gets up-front license fee, research funds, milestones and royalties; Parke-Davis gets exclusive worldwide marketing rights (8/97)

Osiris Therapeutics Inc.*

Novartis Pharma AG (Switzerland)

Research collaboration to develop mesenchymal stem cells (MSC) for treating regenerative diseases (osteoporosis, osteoarthritis), for regenerating bone marrow stroma after cancer chemotherapy, for regenerating cartilage after injury and for certain gene therapy applications

$156M (7.9 0.000000e+00quity)

Novartis will buy $10M in equity (0.69M shares for 7.9take), pay $3M up-front, pay $50M over 5 years to fund R&D and pay $93M in milestones; Novartis will fund cost of all clinical development, regulatory submissions, marketing, sales and manufacturing worldwide (except North America); Osiris gets royalties; Osiris retains right to manufacture for sale in North America any MSC products in fields of osteoporosis, osteoarthritis and cartilage injury (6/97)

Oxford Molecular Group plc (U.K.)

Glaxo Wellcome P.L.C. (NYSE:GLX; U.K.)

Collaboration to expand development of data analysis tools for cheminformatics sequence data

ND

Oxford Molecular will work onsite at Glaxo; further details ND (7/97)

Oxford Molecular Group plc (U.K.)

Glaxo Wellcome P.L.C. (NYSE:GLX; U.K.)

Collaboration to develop Bioinformatics Pipeline (integrated software) to channel flow of DNA sequence data

ND

Glaxo Wellcome will use system for internal research; other details ND (9/97)

Oxford Molecular Group plc (U.K.)

Wyeth-Ayerst Laboratories (division of American Home Products Corp.; NYSE:AHP)

License on Oxford¿s RS3 Discovery scientific information management system

ND

Details ND (8/97)

Oxford Molecular Group plc (U.K.) and Cambridge Combinatorial Ltd.* (U.K.)

Dainippon Pharmaceuticals Co. Ltd. (Japan)

Oxford and Cambridge Combinatorial will jointly provide technical services to design and synthesize combinatorial libraries for Dainippon¿s selected biological targets

ND

Agreement extends for at least 1 year; Dainippon will pay initial fee, research fees and milestones; Dainippon retains exclusive marketing rights; Oxford Molecular gets royalties (7/97)

Penederm Inc.

SmithKline Beecham plc (NYSE: SBH; U.K.)

Agreement to co-develop an undisclosed OTC product of SmithKline¿s via Penederm¿s TopiCare drug delivery polymers

ND

This is 2nd agreement between the companies; SmithKline has option to market finished product worldwide; Penederm gets milestones and royalties as well as revenues from supply of TopiCare compounds (4/97)

Peptide Therapeutics Group plc (U.K.)

SmithKline Beecham plc (NYSE:SBH; U.K.)

Strategic alliance on Peptide¿s allergy vaccine portfolio, which can protect against all allergies in which IgE antibodies mediate the allergic response (vaccines stimulate production of IgG antibodies to block allergic reactions)

$49M (2.8 0.000000e+00quity)

SmithKline gets worldwide rights to market vaccines; SmithKline will be responsible for clinical development and product approval; Peptide gets $10M up-front (including $6M in equity for 2.8take) and $39M over 2 years for license and milestone payments; Peptide also gets royalties (2/97)

Pharmacopeia Inc.

Bristol-Myers Squibb Co. (NYSE:BMY)

Research collaboration to identify and optimize small molecule drug candidates for two chemokine receptors related to inflammatory and immunological diseases; use of Pharmacopeia¿s ECLiPS and high-throughput screening technologies

$40M

3-year agreement; BristolMyers gets combinatorial libraries of chemical structures for testing in its own internal research programs; Pharmacopeia gets upfront payment, annual research funding and milestones for total of $40M; Pharmacopeia could get additional milestones from results of Bristol-Myers¿ screening of its libraries; Pharmacopeia gets royalties (12/97)

Pharmacopeia Inc.

Zeneca Inc. (wholly owned subsidiary of Zeneca Group plc; NYSE: ZEN; U.K.)

Collaboration to use combinatorial chemistry to develop libraries of compounds for Zeneca to screen with its biological assays

ND

3-year agreement; Zeneca will license Pharmacopeia¿s discovery libraries; Zeneca gets exclusive rights to any products; Pharmacopeia gets license fees, milestones and royalties (1/97)

Pharmacyclics Inc.

Alcon Pharmaceuticals Ltd. (affiliate of Alcon Laboratories Inc., a subsidiary of Nestle SA; France)

Assignment of rights to Lu-Tex photosensitizer (lutetium texaphyrin, a synthetic molecule that captures and focuses light energy) for ophthalmic indications, including age-related macular degeneration

ND

Alcon gets worldwide rights to compound for ophthalmic indications; Alcon will conduct and fund all costs for development and product registration worldwide; Pharmacyclics gets up-front payment and milestones as well as royalties (12/97)

Pharmacyclics Inc.

Nycomed ASA (NYSE:NYD; Norway; in process of merging with Amersham International plc to form NycomedAmersham plc)

Licensing agreement on Lu-Tex photosensitizer (lutetium texaphyrin, a synthetic molecule that captures and focuses light energy) for photodynamic treatment of cancer (currently in Phase II trials for breast cancer)

$28M

Nycomed gets exclusive rights to develop and market product in Europe, Asia, and Central and South America; Pharmacyclics gets $14M in license fee, milestones and development costs for initial indication and $14M for subsequent cancer indication; Pharmacyclics gets royalties and retains rights in U.S., Canada and Japan; companies will share costs for product development and approval in U.S. but each will make regulatory submissions in own territories; Pharmacyclics will supply bulk drug substance; Nycomed will make finished product (10/97)

Praecis Pharmaceuticals Inc.*

Synthelabo (subsidiary of L¿Oreal SA; France)

Agreement to develop Praecis¿ drug PPI-149 for treating prostate cancer; drug is luteinizing hormone releasing hormone (LHRH) antagonist (Phase I/II clinical trials ongoing)

$78M (equity; % ND)

Praecis will develop product; Synthelabo will take necessary steps to get regulatory approvals in its territories (Europe, Latin America, Middle East and certain African countries); Praecis retains exclusive rights in rest of world as well as manufacturing rights; Praecis gets signing and milestone payments of $68M as well as $10M equity investment from L¿Oreal; Praecis also gets royalties (6/97)

Procept Inc.

Abbott Laboratories (NYSE:ABT)

Drug screening agreement; use of Abbott¿s SAR by NMR technology for Procept target

ND

Details ND (8/97)

Progenics Pharmaceuticals Inc.

Bristol-Myers Squibb Co. (NYSE:BMY)

License agreement on Progenics¿ cancer vaccines GMK (incorporates GM2 ganglioside) and MGV (incorporates gangliosides GD2 and GM2), which are designed to stimulate patient¿s own immune system; GMK is currently in Phase III trials for malignant melanoma; MGV is in Phase Is for various tumors

ND

Bristol-Myers gets exclusive worldwide license for vaccines; Bristol-Myers will support clinical development and marketing; Progenics gets up-front fees and milestones as well as royalties (7/97)

Progenitor Inc.

SmithKline Beecham Clinical Laboratories Inc. (unit of SmithKline Beecham plc.; NYSE: SBH; U.K.)

License agreement; use of Progenitor¿s gene for hereditary hemochromatosis (HFE gene) and its specific mutations to develop genetic diagnostic test

ND

SmithKline Beecham Clinical Labs has exclusive rights in U.S. and certain other (undisclosed) countries to develop assay and perform centralized lab testing; Progenitor retains rights to therapeutic applications of gene; Progenitor gets annual fees and payments on pertest basis (9/97)

Protein Design Labs Inc.

Teijin Ltd. (Japan)

Licensing agreement on Protein Design¿s antibody humanization technology and use of same to humanize a mouse monoclonal antibody to toxin produced by Escherichia coli 0157 (toxin causes hemolytic uremic syndrome)

ND

Protein Design will humanize the antibody for Teijin; Teijin gets non-exclusive license under Protein Design¿s patents; financial terms ND (4/97)

Qiagen NV (the Netherlands)

Organon Teknika BV (unit of Akzo Nobel NV; the Netherlands)

Licensing agreement on Organon¿s ¿boom¿ patents (nucleic acid purification technology)

ND

Qiagen gets worldwide non-exclusive license to develop, manufacture and market products using technology in all markets and for all applications with no field-ofuse limitations (11/97)

Regeneron Pharmaceuticals Inc.

The Procter & Gamble Co. (NYSE:PG)

Major research collaboration on drugs for arthritis, cancer and cardiovascular disease; will include all Regeneron research programs now underway (angiopoietins; muscle-specific growth factor receptor and bone growth antagonists) except programs it has already partnered

$135M (13.7 0.000000e+00quity)

10-year agreement; Regeneron gets $135M over 1st 5 years (includes $75M in research funding and $60M in equity for a 13.7take; P&G already held 30nder a 12/96 agreement, so its total stake is now 16.7%; P&G will limit its ownership to 20% maximum); P&G initially bought $43M in equity (4.35M shares at $9.87 each, as well as 5-year warrants for 1.35M shares) and will buy additional $17M in equity over 1st 5 years; P&G gets rights to Regeneron¿s current technology as well as new technology developed under the collaboration; companies will jointly develop and market products worldwide and share profits equally; clinical testing expenses will be shared equally for entire 10 years (5/97)

Repligen Corp.

Pfizer Inc. (NYSE:PFE)

Collaboration on small molecule immunostimulatory agents; also to construct high-throughput screening assay for Pfizer¿s compound library

ND

Repligen will supply reagents to Pfizer for construction of screening assay; companies will jointly evaluate lead compounds; Pfizer will develop and market any new drug; Repligen gets up-front technology access fee and milestones (1/97)

Ribozyme Pharmaceuticals Inc.

Parke-Davis (division of Warner-Lambert Co.; NYSE: WLA)

Letter of intent on collaboration to evaluate specific disease-related genes for drug intervention using Ribozyme¿s target validation technology (involves use of ribozymes to discover gene function and validate gene targets)

ND

Ribozyme Pharmaceuticals will design and synthesize ribozymes against target genes designated by Parke-Davis; collaboration subject to negotiation of definitive agreement; financial terms ND (12/97)

Ribozyme Pharmaceuticals Inc.

Schering AG (Germany)

Research collaboration; focus on use of ribozymes to validate therapeutic targets (in broad range of diseases) as well as develop ribozymes as therapeutic agents per se

$60M (equity; % ND)

5-year agreement; Schering subsidiary Berlex Laboratories Inc. will provide candidate targets and has options to commercialize any resulting products; Schering has rights to ribozymes identified for its targets but if it does not exercise those rights, they return to Ribozyme Pharmaceuticals; Schering will buy $5M in equity over next year and will make loan of $2M/year for 5 years; loans are convertible into Ribozyme equity at Schering¿s option; Schering will also pay $2M/year for 5 years in research funding, as well as milestones, success fees and royalties; Ribozyme Pharmaceuticals will manufacture synthetic ribozyme products (4/97)

RTP Pharma Inc. (Canadian affiliate of Research Triangle Pharmaceuticals Inc.*)

AMRAD Corp. Ltd. (Australia)

License agreement on RTP¿s reformulated version of anesthetic agent propofol (via Insoluble Drug Delivery technology)

ND

AMRAD has exclusive rights to product; RTP gets milestones and royalties (9/97)

Scios Inc.

Abbott Laboratories (NYSE:ABT)

Licensing agreement on Scios¿ technology and patents related to cardiac hormone BNP (B-type natriuretic peptide) to be used as cardiovascular marker

ND

Abbott gets semi-exclusive license to technology and patents; Abbott will evaluate clinical and commercial utility of diagnostic test for BNP (5/97)

Scios Inc.

The DuPont Merck Pharmaceutical Co.

Research collaboration on drugs that prevent or retard disease progression in Alzheimer¿s; initial focus on use of Scios¿ high-throughput screens on DuPont Merck compounds to identify leads

$3M (equity; % ND)

DuPont Merck will fund research and be responsible for developing and commercializing products; DuPont Merck will make $3M equity investment in Scios and pay milestones and royalties on sales (11/97)

Scios Inc.

Eli Lilly & Co. (NYSE:LLY)

Research collaboration on drugs that prevent or retard progression of Alzheimer¿s disease (including development of screening assays for product candidates)

ND

Lilly will fund research and will have 1st option to develop any products; Scios may elect to develop other candidates; the commercializing partner will pay milestones and royalties to the other partner; both companies can use any technology developed in the collaboration; financial terms ND (5/97)

Scotia Holdings plc (Scotland)

Boehringer Ingelheim GmbH (Germany) and Kyowa Hakko Kogyo Co. Ltd. (Japan)

License agreements on Scotia¿s photodynamic therapy agent Foscan for treating cancer and premalignant conditions (currently in Phase III international trials in head and neck and laryngeal cancer)

$54M

Boehringer Ingelheim gets exclusive rights to develop and market product in North and South America and Europe; Kyowa Hakko gets exclusive rights in Japan; Scotia retains rights in other territories; Scotia gets total of $54M in upfront and milestone payments; Scotia will manufacture product for both partners and gets payments for product supply; Scotia retains responsibility for research, preclinical work and current Phase III trials (9/97)

Scriptgen Pharmaceuticals Inc. *

Eli Lilly & Co. (NYSE:LLY)

Drug discovery collaboration via Scriptgen¿s ATLAS (any target ligand affinity screen) technology against drug targets identified by Lilly

ND

2-year agreement; Scriptgen gets front-end fees, R&D funds, milestones and royalties (5/97)

Scriptgen Pharmaceuticals Inc. *

Hoechst Marion Roussel Inc. (subsidiary of Hoechst AG; Germany)

Collaboration to identify fungal targets and develop antifungal drugs via Scriptgen¿s highthroughput target identification and validation systems as well as affinity screens

$9M (equity; % ND)

Scriptgen gets $6M in technology access fees (through 1/98) plus $3M equity investment concurrent with Scriptgen¿s IPO; Scriptgen also gets R&D funding, milestones and royalties; Hoechst Marion will actively participate in research; Hoechst Marion will be responsible for global product development and marketing (10/97)

SemBioSys Genetics Inc.* (Canada)

Dow AgroSciences (formerly DowElanco; subsidiary of The Dow Chemical Co.; NYSE: DOW)

Strategic alliance on development of recombinant plants to produce proteins for use as therapeutics, vaccines, industrial products and feed additives (molecular farming technology)

$4M (equity; % ND)

5-year agreement; Dow AgroSciences has invested $4M so far and has options to provide ¿significant¿ additional funding in exchange for equity (12/97)

Sepracor Inc.

Schering-Plough Corp. (NYSE:SGP)

License agreement on Sepracor¿s patent on DCL (descarboethocyloratadine, a metabolite of the active agent in Claritin nonsedating antihistamine)

$5M

Schering-Plough gets exclusive worldwide rights to DCL; Sepracor gets up-front license fee of $5M and royalties that escalate over time (12/97)

Seq Ltd.*

Zeneca Pharmaceuticals Inc. (wholly owned subsidiary of Zeneca Group plc; NYSE: ZEN; U.K.)

Agreement to develop SEQ¿s DNA sequencing technology Single Molecule Sequencing by Fluorescence

ND

Zeneca will provide funding to develop technology; Zeneca gets access to SEQ¿s gene sequencing services on preferential terms; Zeneca has option to purchase significant equity interest in SEQ (9/97)

Sequana Therapeutics Inc. (since merged with Arris Pharmaceutical Corp. to form Axys Pharmaceuticals Inc.)

Parke-Davis (division of Warner-Lambert Co.; NYSE: WLA)

Broad-based genomics alliance to develop therapeutics for treating schizophrenia and bipolar disorder via Sequana¿s capabilities in gene discovery, functional genomics, bioinformatics and high-throughput screening

$103M

Sequana gets $103M in combination of up-front licensing fees, research funding and milestones; Sequana also gets royalties on sales of any small molecule therapeutics; 5-year alliance is extendable in 1-year increments to 8 years with concomitant increases in research funding; Parke-Davis gets exclusive worldwide rights to any small molecule therapeutics; Sequana retains worldwide rights to recombinant protein, antisense, gene therapy, vaccine, diagnostic, prognostic and pharmacogenetic products and services; ParkeDavis gets non-exclusive license to use certain of Sequana¿s bioinformatics software tools (11/97)

Sequana Therapeutics Inc. (since merged with Arris Pharmaceutical Corp. to form Axys Pharmaceuticals Inc.)

PE Applied Biosystems (division of Perkin-Elmer Corp.; NYSE:PKN)

Letter of intent to form DNA sequencing joint venture in People¿s Republic of China, which will be called GeneCore Biotechnologies Inc.

ND

Sequana and PE Applied Biosystems will each own 47.50f joint venture and SiniWest Holdings Inc. will own 5%; further details ND (1/97)

Sequus Pharmaceuticals Inc.

Bayer AG (Germany)

Sequus will formulate Bayer¿s antibiotic drug Ciprofloxacin into long-circulating Stealth liposomes

ND

Sequus gets milestone payments and royalties (7/97)

Seragen Inc.

U.S. Surgical Corp. (NYSE:USS)

Option agreement on Seragen¿s epidermal growth factor fusion protein DAB389EGF for treating restenosis following cardiovascular procedures

$32.5M

U.S. Surgical has option on worldwide marketing rights and can exercise it any time over next 15 months for $5M; Seragen also gets $5M upfront; if it exercises option, U.S. Surgical will fund clinical trials; Seragen gets $22.5M in milestones as well as royalties (7/97)

Sibia Neurosciences Inc.

Meiji Seika Kaisha Ltd. (Japan)

Licensing agreement on SIB-1508Y (nicotinic acetylcholine receptor agonist) as a first-of-type treatment for Parkinson¿s disease

ND

Sibia gets licensing fee, milestones and royalties; Sibia will supply product to Meiji for clinical use and retains manufacturing rights; Meiji gets product rights in Japan, China and certain other Asian counties (3/97)

Siga Pharmaceuticals Inc.

Wyeth-Ayerst Laboratories (division of American Home Products Corp.; NYSE:AHP)

Research collaboration on anti-infectives for preventing and treating human and animal Grampositive bacterial infections; based on use of highthroughput screening to identify protease inhibitors that block normal surface protein anchoring of bacteria to mucosal surfaces

$25M

SIGA could get $25M in up-front and milestone payments; WyethAyerst will help fund product development; SIGA gets royalties on product sales (7/97)

Signal Pharmaceuticals Inc.*

Ares-Serono Group (Switzerland)

Collaboration to identify small molecule modulators in the NF-kB gene regulation pathway (includes broad set of genes for inflammatory molecules); key targets are proteins IKK-1, IKK-2 and a 3rd regulatory protein as well as NF-kB inducing kinase

$59M (equity; % ND)

Signal gets $8M equity investment and $9M over 3 years to fund research plus about $42M in milestones (at least $10M for each product resulting from research); Signal also gets royalties; AresSerono gets worldwide rights to all products; Signal retains option to co-promote in U.S.; Signal responsible for target identification and validation, high-throughput screening and lead optimization; AresSerono will conduct all further product development, approvals and marketing for all indications except in Asia (12/97)

Sugen Inc.

Hoechst Marion Roussel Inc. (subsidiary of Hoechst AG; Germany)

Sugen acquired option on oral cancer drug candidate that Hoechst Marion had developed for different indication

ND

Sugen acquired option on exclusive worldwide license to drug candidate; Hoechst Marion will supply research quantities of compound and data package; if Sugen exercises option, it will pay Hoechst Marion option fee, milestones and royalties; Hoechst Marion retains right of 1st refusal to sublicense product for markets outside North America (4/97)

Synaptic Pharmaceutical Corp.

Warner-Lambert Co. (NYSE:WLA)

Collaborative research and license agreement on compounds that act on receptors for neurotransmitter galanin for multiple therapeutic indications (including Alzheimer¿s disease, depression, pain and eating disorders)

$34M

Synaptic gets $34M in milestones for 1st two compounds and additional milestones for other drugs identified in collaboration; Warner-Lambert gets exclusive worldwide rights to develop, manufacture and market products; in 1st stage of collaboration (18 months) each party will fund its own research and use galanin receptor assays to identify and characterize drug leads; in 2nd stage (3 years) Warner-Lambert will fund R&D and can be required to buy Synaptic stock; Synaptic gets royalties (8/97)

T Cell Sciences Inc.

Novartis Pharma AG (Switzerland)

Option agreement on TP10 (soluble complement receptor 1; inhibits complement activation) for use in xenoand allotransplantation

$25M (equity; % ND)

T Cell gets $5M in annual option fees and cost of clinical supplies of TP10 in return for granting Novartis a 2-year option to license worldwide exclusive rights (except Japan) to TP10 in fields of xenoand allo-transplantation; if Novartis exercises option, T Cell gets $20M in equity investment, licensing fees and milestones; T Cell could also get additional research funding and royalties; T Cell retains rights to all other indications except those already assigned to other partners in Japan (10/97)

Terrapin Technologies Inc.*

Hoffmann-La Roche Inc.(unit of Roche Holding Ltd.; Switzerland)

Agreement on Terrapin¿s orally active small molecule therapeutic that acts as a myelostimulant (to accelerate recovery of bone marrow cells after chemotherapy)

ND

Hoffmann-La Roche will evaluate product and has right to acquire the commercial rights; further details ND (3/97)

Terrapin Technologies Inc.*

Sanwa Kagaku Kenkyusho Co. Ltd. (Japan)

Collaboration to develop a drug for treating Type II diabetes and insulin resistance via Terrapin¿s molecular fingerprinting technology (TRAP); target is orally active compounds that lower blood glucose by acting on insulin signal transduction pathway

$22.5M (equity; % ND)

Terrapin will get $22.5M in license fees, R&D funds, milestones and equity purchase; Sanwa gets rights to commercialize in Japan and other Asian countries; Terrapin retains rights elsewhere; Terrapin gets royalties; separately, the companies entered a screening agreement by which Terrapin will identify compounds for Sanwa¿s other disease targets (1/97)

Terrapin Technologies Inc.*

Sosei Co. Ltd. (Japan)

Drug screening alliance; will use Terrapin¿s molecular fingerprinting technology (TRAP) to identify lead compounds for Sosei¿s disease targets from Terrapin¿s small molecule library

ND

Companies will jointly own rights to any discovered compounds; once identified, companies will decide whether to develop the compounds internally or to outlicense them (1/97)

Terrapin Technologies Inc.*

Taiho Pharmaceutical Co. Ltd. (Japan)

Agreement to develop Terrapin¿s anticancer agent TER 286 (specific compound designed to become toxic only in presence of glutathione S-transferase, an enzyme present in elevated amounts in many chemotherapy resistant solid tumors)

ND

Taiho will fund R&D; Terrapin will take product through preparation of IND; at that point, firms will sign a license agreement giving Taiho commercialization rights in Japan and other Asian countries; Terrapin retains rights elsewhere (8/97)

TheraTech Inc.

Eli Lilly & Co. (NYSE:LLY)

Multiproduct collaborative agreement on oral transmucosal delivery systems for Lilly¿s peptide drugs (most of which are in endocrine field)

ND

TheraTech gets initial fees, research funds, milestones and royalties; Lilly gets exclusive rights to commercialize products (1/97)

TheraTech Inc.

The Procter and Gamble Co. (NYSE:PG)

Agreement to develop transdermal testosterone and combination estradiol/testosterone hormone replacement patches for women (testosterone patch currently in Phase II trials for treating diminished libido in surgically menopausal women)

$35M

Companies will work together on clinical development of products; Procter and Gamble will fund all development; TheraTech gets R&D payments and milestones of $35M as well as royalties; TheraTech will manufacture products and retains certain co-promotion rights; Procter and Gamble gets worldwide rights (except Asia) (12/97)

Titan Pharmaceuticals Inc.

Hoechst Marion Roussel Inc. (subsidiary of Hoechst AG; Germany)

Licensing agreement on Hoechst Marion¿s antipsychotic drug Iloperidone (will enter Phase III trials 1H:97 for treating schizophrenia and related disorders)

ND

Titan licensed exclusive worldwide rights to develop and market drug; further details ND (1/97)

Titan Pharmaceuticals Inc.

Novartis Pharma AG (Switzerland)

Agreement on Titan¿s antipsychotic small molecule drug Iloperidone (blocks serotonin and dopamine); in clinical development for treating schizophrenia and related disorders

$38M (equity; % ND)

Titan gets up-front payment of $18M in license fees and reimbursement of R&D costs plus a $5M equity investment; Titan will get $5M milestone when it submits an NDA in U.S. or Europe and $10M on product approval; Novartis will fund Phase III trials and product registration costs worldwide (except Japan); Titan gets royalties on sales (11/97)

Transcell Technologies Inc. (majorityowned subsidiary of Interneuron Pharmaceuticals Inc.)

Merck & Co. Inc. (NYSE:MRK)

Collaborative research and license agreement on antibacterial agents; Transcell will use its combinatorial carbohydrate technology to make libraries of analogues of two distinct structural classes of antibiotics for biological evaluation

$48M

Merck gets license on any products and has option to extend collaboration to include all antibacterial drugs; Transcell gets initial licensing fee and research support over 2 years as well as milestones in each program; if products from both programs are approved by FDA, Transcell gets total of $48M; it also gets royalties (7/97)

Trega Biosciences Inc.

Ono Pharmaceutical Co. Ltd. (Japan)

R&D agreement on orally active small molecules for treating diseases mediated by melanocortin receptor pathway through cytokine regulation; focus on compounds that are active at melanocortin receptor subtype MC-1 (for inflammatory diseases)

$25M

Agreement includes signing payment, research support and milestones of $25M total as well as royalties; Trega will screen its combinatorial chemistry libraries as well as compound files from Ono for active compounds; Trega will optimize drug candidates and conduct preclinical tests; Ono gets rights in Far East; companies will co-market in Europe; Trega gets rest of world including North America (6/97)

Tripos Inc.

Bristol-Myers Squibb Co. (NYSE:BMY)

Bristol-Myers gets access to Tripos¿ ChemSpace technology for design and analysis of combinatorial libraries and related data

ND

3-year agreement; Tripos gets up-front fee; further details ND (7/97)

Tripos Inc.

Pfizer Inc. (NYSE:PFE)

Collaboration on new software products for drug discovery (especially for analysis of chemical and biological data generated by highthroughput chemistry and biology screening)

ND

Pfizer will fund R&D of new software tools to meet its needs in cheminformatics (7/97)

Tularik Inc.*

Roche Bioscience (division of Roche Holding Ltd.; Switzerland)

Collaboration on orally active drugs that regulate targets within pro-inflammatory signaling pathways; targets include regulatory proteins discovered at Tularik

ND

5-year collaboration; financial terms ND but Roche will fund research; each company retains marketing rights for drugs to treat specific (undisclosed) diseases (7/97)

Unigene Laboratories Inc.

Parke-Davis (division of Warner-Lambert Co.; NYSE:WLA)

License agreement on Unigene¿s oral calcitonin for treating osteoporosis (Phase I trials completed)

$50M (equity; % ND)

Warner-Lambert will assume responsibility for development and marketing; Unigene will provide analytical support services and be the exclusive supplier of bulk active raw material; if product gets approved by FDA, Unigene will get up-front and milestone payments of $50M; Warner-Lambert will also buy equity in Unigene (letter of intent 6/97; definitive agreement 7/97)

Vanguard Medica Group plc (U.K.)

Abbott Laboratories (NYSE:ABT)

Licensing agreement on VML 530 (oral dose, inhibitor of 5-lipoxygenase activating protein) for treating asthma

$3M (equity; % ND)

Abbott has option to develop and commercialize product after Vanguard completes Phase II trials (now in preclinical stage); if it exercises option, Abbott will buy US$3M in new common stock of Vanguard (at market price) and Vanguard gets royalties on sales (10/97)

Vanguard Medica Group plc (U.K.)

Sankyo Co. Ltd. (Japan)

Licensing agreement on VML 252 (oral dose, calcium-free phosphate binding agent) for treating hyperphosphatemia (elevated blood phosphate) (currently in U.S. Phase II trial in patients with chronic kidney failure)

ND

Sankyo gets exclusive rights to develop and market product in Japan and Far East; Sankyo will make series of payments for rights and will cover part of development costs; Vanguard will continue clinical development in U.S. and Europe; Vanguard will provide bulk compound to Sankyo for its own trials; Vanguard gets royalties on Sankyo¿s sales (10/97)

Verigen Inc.*

Italchimici SpA (Italy)

Licensing agreement on Verigen¿s PASSTNFalpha product (porcinederived polyclonal antibody to tumor necrosis factor-alpha) for use in treating rheumatoid arthritis and Crohn¿s disease

ND

Italchimici will develop and market product in Italy; Verigen gets up-front license fee and royalties; Verigen retains manufacturing rights (10/97)

Vertex Pharmaceuticals Inc.

Eli Lilly & Co. (NYSE:LLY)

Strategic alliance on orally active protease inhibitors for treating chronic hepatitis C virus infection

$50M (equity; % ND)

Lilly will pay $40M for research support and milestones; Lilly will also buy $10M in Vertex stock; companies will jointly manage R&D, manufacturing and marketing; Vertex has option to supply all of Lilly¿s commercial needs for drug; if it exercises that, Vertex will get drug supply payments instead of royalties outside U.S. and Japan; Vertex has option to co-promote drug in U.S. and selected territories (6/97)

Vertex Pharmaceuticals Inc.

Kissei Pharmaceutical Co. Ltd. (Japan)

Collaboration to develop orally active inhibitors of Vertex¿s p38 mitogen-activated protein (MAP) kinase for treating inflammatory and neurological diseases

$22M

3-year collaboration; Vertex gets license fee, research support and milestones totaling $22M; Kissei will develop and commercialize product in its territories; Kissei has exclusive rights in Japan and certain Southeast Asian countries and semi-exclusive rights in China, Taiwan and South Korea; Vertex retains rights in U.S., Canada, Europe and rest of world; Vertex will supply bulk drug material to Kissei and gets drug supply payments and royalties (9/97)

Vical Inc.

Merck & Co. Inc. (NYSE:MRK)

License agreement on use of Vical¿s ¿naked¿ DNA technology to deliver certain growth factors (at least one of which stimulates revascularization of tissues)

$35M

Vical gets initial payment of $2M in deal worth $35M, plus royalties; Merck gets license and options on use with other proteins (9/97)

Vical Inc.

Rhone-Poulenc Rorer Inc. (subsidiary of RhonePoulenc Group; NYSE:RP; France)

License on use of Vical¿s ¿naked¿ DNA gene delivery technology to develop certain gene therapy products for treating neurodegenerative diseases

$1M

Rhone-Poulenc Rorer gets exclusive worldwide license to technology (which will be used by its division RPR Gencell); Vical gets initial fee of $1M plus milestones and royalties (10/97)

VIMRx Pharmaceuticals Inc.

Baxter Healthcare Corp. (subsidiary of Baxter International Inc.; NYSE:BAX)

Formation of new cell therapy company (not yet named) to develop treatments for cancer and other diseases; will combine Baxter¿s ex vivo cellular selection and storage business with VIMRx¿s access to gene therapy and genomics technology

$130M (equity; % ND)

New company will receive the assets of Baxter¿s immunotherapy division; VIMRx gets 800wnership in exchange for 11M VIMRx common shares ($50M) and convertible preferred shares worth about $40M; Baxter will also provide $30M and VIMRx will provide $10M to new company as initial funding; new company will pay Baxter $21M in milestones over several years; Baxter will sublicense its CD34 antibody used in selection technology to new company (letter of intent 6/97; definitive agreement 10/97; approved by VIMRx shareholders 12/97)

Vion Pharmaceuticals Inc.

Boehringer Ingelheim GmbH (Germany)

Licensing agreement on Vion¿s Promycin anticancer agent (a bioreductive alkylating agent; currently in Phase III trials as adjunct to radiation therapy for treating head and neck cancer)

$50M (equity; % ND)

Boehringer Ingelheim gets exclusive rights to product outside North America; Vion gets exclusive co-promotion rights in North America; Vion gets up-front license fee, milestones and royalties; companies will share development costs worldwide; Boehringer Ingelheim will buy $3M equity in Vion (at premium to market); Vion will manufacture and supply product for all territories (11/97)

Virus Research Institute Inc.

SmithKline Beecham plc (NYSE:SBH; U.K.)

Collaboration on Virus Research¿s live oral rotavirus vaccine (virus causes acute diarrhea and dehydration in infants)

ND

Virus Research gets license fees, milestones and royalties; SmithKline gets exclusive worldwide rights; Virus Research will continue to conduct U.S. Phase II clinical trials, after which SmithKline has right to assume responsibility for all subsequent development; SmithKline Biologicals will manufacture product (12/97)

Visible Genetics Inc. (Canada)

Consolidated Laboratory Services

R&D collaboration on 2 diagnostic tests for HIV (quantitative viral load test; full sequence-based test)

ND

Visible Genetics will adapt its testing methods to analysis and sequencing of Consolidated¿s HIV-1 samples; companies will collaborate on early-stage clinical trials; Visible Genetics gets exclusive rights to sell both tests (3/97)

Visible Genetics Inc.

Roche Molecular Systems Inc. and Hoffmann-La Roche Ltd. (Switzerland)

License on Roche¿s polymerase chain reaction (PCR) technology for use in DNAbased diagnostic sequencing (Visible Genetics¿ OpenGene system)

ND

Visible Genetics gets non-exclusive limited rights to PCR technology, which it can use to develop, market and sell diagnostic kits and integrated systems; Roche Molecular gets limited option to distribute certain diagnostics (8/97)

Xenova Discovery Ltd. (subsidiary of Xenova Group plc; U.K.)

EG&G Wallac (Finland)

Formation of joint venture, to be called Advant; to provide customized products and services (e.g., highthroughput screens) for identification of new drug leads

ND

Partners will each license certain proprietary technologies to the joint venture; partners will share profits (12/97)

Xenova Group plc (U.K.)

Parke-Davis (division of WarnerLambert Co.; NYSE:WLA)

Drug discovery collaboration based on use of Xenova¿s NatChem natural products system

ND

Xenova will provide Parke-Davis with drug discovery chemicals from its NatChem system for screening Parke-Davis compounds; once leads selected, Xenova will isolate and identify active chemicals and give them to Parke-Davis to develop; Xenova gets milestones and royalties; Xenova has exclusive marketing rights in Europe to any cancer products that result (5/97)

Xenova Group plc (U.K.)

Zeneca Ltd. (NYSE:ZEN; U.K.)

Drug discovery collaboration via Xenova¿s natural product compound library (plant, fungal and microbial sources) and Xenova¿s QTC technology

ND

Xenova will supply libraries to Zeneca for screening; Zeneca gets worldwide exclusive rights to develop and commercialize selected compounds; Xenova gets fees for providing libraries, as well as milestones and royalties; drug leads may revert to Xenova in some cases (Zeneca invested $3.2M in Xenova¿s 12/96 public offering, for a 4take) (3/97)

Xoma Corp.

Eli Lilly & Co. (NYSE:LLY)

Licensing of Xoma¿s bacterial cell expression technology for producing recombinant proteins (includes AraB promoter for control of expression, pelB secretion system and genetically engineered Escherichia coli host cell line)

ND

Xoma granted non-exclusive license in exchange for up-front fee, milestone payments and royalties on sales (5/97)

Xoma Corp.

Pharmacia & Upjohn Inc. (NYSE:PNU; U.K.)

Licensing of Xoma¿s bacterial cell expression technology for producing recombinant proteins (includes AraB promoter for control of expression, pelB secretion system and genetically engineered Escherichia coli host cell line)

ND

Xoma granted non-exclusive license in exchange for up-front fee, milestone payments and royalties on sales (5/97)


No Comments